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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
                                                           INTRODUCTION 
 
     The central nervous system is made up of the brain and the spinal cord and 
their coverings . They are unique in their ability to receive, store and transmit 
information.  
Brain tumors though not frequent contribute significantly to morbidity 
because of the mental alterations, neurological deficits and their relatively poor 
survival rate. Hence the social burden of the central nervous system tumors is 
just as large as that of other tumors. The central nervous system tumors are 
unique in a way that it has some special features. In contrast to other sites 
benign tumors may have the potential to become life threatening. So the 
malignant potential of CNS tumors is of two patterns, anatomic and biologic. 
The former includes deeply seated lesions that could not be reached by the 
surgeon, and so may progress until become fatal, while the latter includes 
aggressive tumors that grow rapidly with the resulting neuropil invasion and 
destruction. Nevertheless CNS cancers do not fit exactly the general definition 
of malignancy as they rarely spread outside their primary location, despite the 
fact that some tumors tend to seed the neuraxis via CSF44. 
Space occupying primary neoplasms of the CNS and its covering account for 
about 9% of all primary neoplasms of the human body and metastatic tumors 
constitute about 5% 75. Among the intracranial space occupying tumors those of 
the central neurogenic origin claim priority in number and complexity. These 
are the tumors derived from parenchymatous neuroepithelial elements of the 
CNS excluding microglia; and they are widely credited to account for 40-50% 
of all intracranial  space occupying tumors62 
Systematic study of tumors of the  CNS began when Bailey and Cushing 
started their studies in the early 1920’s. Over the past three decades, many 
reports suggested that both incidence and pattern of intracranial neoplasia are 
subject to considerable geographic and racial variations. Population based 
cancer registries are established for a better understanding of the epidemiology . 
knowledge of the regional peculiarities of these lesions may therefore help in 
identification of possible risk factors. Delay in reporting are a reality and a 
known issue influencing registry completeness for achieving data quality goals. 
Ultimately it will affect the magnitude of rate calculation leading on to cancer 
rate underestimation, that will hinder the planning measures for updated facility 
treatment centers. Hence it is essential that quality control editing of the data 
with incorporation of updates to the cancer registration has to be refined every 
year.   
Primary brain tumors continue to be among the top ten causes of cancer 
related deaths in the world. As per the CBTRUS( Central Brain Tumor Registry 
of the United States), the annual incidence of the tumors of the CNS  is  3.9 per 
100,000 persons for intracranial tumors. Global differences in rates tend to 
correspond to the level of economic development, with the highest rates in 
North America, Australia, and Western Europe and the lowest rates in Asia, 
South and central America. Regional differences in incidence rates of CNS 
tumors were also noted in India. According to the data obtained from various  
cancer registries in India the age specific ,world adjusted incidence rate  
accounts to be 5.1 per 100,000 persons. The highest incidence of brain tumors 
was reported from Sikkim and lowest in Mizoram state.75 
 Risk factors causing brain tumors remain uncertain. Racial differences, 
exposure to radiation, chemical exposure in working in the rubber, 
petrochemical or metal industries and family history of brain cancer are 
postulated to increase the risk of brain tumors. Excessive use of mobile phones 
resulting in exposure to electromagnetic waves has triggered a great inquisition 
among researchers to label it as a cause for brain tumors, but its 
etiopathogenesis is still not proven. So epidemiological studies of brain tumors 
in depth is necessary to understand the etiology of risk factors. 
 An estimated 2400 children between the ages of 0-19 years are diagnosed 
with invasive primary CNS tumors in the United  States each year109. The 
incidence of CNS tumors  in children  < 20 years is 4.58 per 100,000 person 
years. (CBTRUS report 2009). Brain tumors are second only in frequency to 
acute lymphoblastic leukemia in children. Pilocytic astrocytomas, malignant 
glioma and medulloblastoma are the commonest tumors. The incidence of CNS 
tumors in children was found to have increased in the recent years. This 
incidence has been mainly attributed to the introduction of Magnetic Resonance 
Imaging (MRI) in the 1980s that improved the detection of low grade tumors 
previously unidentifiable by other less optimal imaging modalities. 
 A comparison using international studies of primary intracranial tumors 
results in an average male to female ratio of 1.4:1 across geographical areas. 
However sex ratios varies considerably by histological types. Gliomas are 
higher in males and females show a predominance with meningiomas.1 
The CNS tumors have always been a cause of concern to the pathologist due 
to the wide variety in their appearances. Diagnosing a CNS tumor posses a 
significant challenge but the gold standard used for the definitive diagnosis of 
CNS tumors is the microscopic examination of the tumor 
The WHO 2007 classification is the latest updated system that has been 
edited by two neuropathologists ( Dr. Louis and Dr. Weistler) and two 
molecular pathologists ( Dr.Ohgaki and Dr.Cavenee), reflecting the gradual 
shift in modern pathology. About 86 major types of CNS tumors and their 
variants have been listed.52 
 Grading is fundamental for optimal prognostication and deciding on the 
choice of therapy. Histological grading of CNS tumors can be challenging 
despite criteria given by WHO more often due to limited tumor material 
provided. The number of mitosis is of paramount importance but can be hard to 
identify in the haematoxylin and eosin stained sections. Since proliferative 
activity is  a reliable method to assess tumor biology estimation of proliferative 
activity has gained much enthusiasm and there has been continuous research to 
employ biological markers such as Ki -67 as an adjunct to conventional 
morphological variables.  
The diagnostic tools in the investigation of brain tumors are expanding 
greatly with advances in imaging studies. These modalities are complementary 
to the diagnosis and are not confirmatory. Immunohistochemistry is an essential 
clinical research tool in medical science in this era. It helps in making specific 
confirmatory diagnosis by detecting lesion specific markers. It also helps in 
predicting the final outcome of neoplastic lesion by detecting various prognostic 
markers 
Ki -67 is a novel non histone nuclear protein that is expressed in the active 
phases of the cell cycle and thus labelling with the monoclonal antibody against 
this antigen readily identifies cells that are actively proliferating. Ki-67 labelling 
correlated well and yielded credible results in our study. However this marker 
should not be used alone but in combination with established histopathological 
criteria of malignancy.  
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AIM OF THE STUDY 
 
1. To study the incidence of various CNS neoplasms reported in the 
department of Pathology, at Thanjavur Medical college. 
2. To evaluate the anatomical distribution of CNS neoplasms. 
3. To determine the age and sex wise distribution of CNS neoplasms of 
various grades. 
4. To histologically grade CNS neoplasms according to WHO 2007 
criteria. 
5. To evaluate the occurrence of  various childhood  brain  tumors  
6. To evaluate the expression of Ki - 67  in different CNS neoplasms.             
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                                       MATERIALS AND METHODS 
This study was carried out in the department of Pathology from January 
2010 to May 2012 (29 months). All specimens sent with the clinical diagnosis 
of central nervous system tumors were studied and only histologically 
diagnosed CNS neoplasms were included. All the tumors were graded 
according to the WHO criteria. 
Exclusion criteria: 
1. Reactive lesions 
2. CNS infections 
3. Non neoplastic cystic lesions 
The specimens were mostly biopsies received as an aggregate ranging 
from 0.5 cc to 5 cc. There was one specimen of meningioma which was 
received as  a well circumscribed mass measuring 5  x 5 cms .(fig 1)  A detailed 
history with particular attention to clinical symptoms and signs were noted. Site 
of the tumors were recorded and correlated  with the computed tomography 
findings.  
 All the specimens were fixed in 10% neutral formalin and were subjected 
to histopathological examination. Sections of 3-5 micron thickness were made 
and routine staining with haematoxylin and eosin was done.( Annexure - III) 
 Reticulin stain was applied to one case of Gliosarcoma for confirmation 
of the sarcomatous component ( Annexure- IV) along with GFAP for 
highlighting the glial elements for the same case. 
 Immunohistochemistry was done with Ki 67 antibody for selected cases 
that included different tumors of various grades. Immunohistochemistry was 
done based on the peroxidise method  with a standard HRP kit. (Annexure- V). 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
REVIEW OF LITERATURE 
ANATOMY  
            The CNS consists of the brain and the spinal cord covered by the 
meninges. All parts of the CNS are made up of the gray matter containing 
mainly the neuronal cell bodies and the white matter that has the axons. The 
supporting cells are the neuroglia that comprise four principle  type of glial cells 
– astrocytes, oligodendrocytes, microglia and ependymal cells. The astrocytes 
are highly branched cells that pack the interstices between the neurones. They 
provide mechanical support and mediate exchange of metabolites and form 
blood brain barrier. It also has an important role in the repair of CNS tissue after 
injury. Oligodendrocytes are CNS equivalents of the Schwann cells of the PNS 
and for myelin. The microglia are CNS representatives of the monocyte- 
macrophage system. Ependymal cells form the specialised epithelium which 
lines the ventricles and spinal canal and secrete the CSF120 
EPIDEMIOLOGY OF BRAIN TUMORS: 
According to the data of the CBTRUS ( Central Brain Tumor Registry of the 
United States) 12  the overall rate of occurrence of CNS tumors is about 19.34 
per 100,000 person years. N.Manoharan et al75 showed that the CNS tumors 
were more common in the male population (65%) than in the females in India. 
 
 
ETIOLOGY OF BRAIN TUMORS   
Exposure to ionising  radiation is the only well documented environmental risk 
factor for the development of gliomas. The mutations in the genes causing brain 
tumors are usually the tumor suppressor genes and the protooncogenes2. A 
number of hereditary syndromes  as shown in the table are asociated with brain  
tumors. Astrocytomas have EGFR amplifications and PDGFR amplifications 
sometimes associated with LOH 10q(PTEN) and LOH at 9p( INK 4a). 
Oligodendrogliomas have del 1p and 19q.  In meningiomas portions of 
chromosome 22 q are lost. The results of neither the case-control studies nor 
the meta-analysis conducted by  the INTERPHONE study, coordinated by the 
International Agency for Research on Cancer (IARC) provide consistent 
support for an association between mobile phone use and brain tumours.92 
Common genetic syndromes and associated tumors109 
SYNDROME GENE CHROMOSOME TUMORS 
Neurofibromatosis Type I NF-1 17q11 
Optic gliomas, 
Asrocytomas 
Neurofibromas 
 
Neurofibromatosis Type II NF-2 22q12 
Vestibular schwannomas 
Meningiomas 
Spinal cord ependymomas 
Von Hippel Lindau VHL 3p25 Cerebellar hemangioblastomas 
Tuberous sclerosis TSC1 and TSC2 9q34 and 16p13 Subependymal giant cell 
astrocytoma 
Turcot APC, MLH1,PMS-2 5q21,3p21,7p21 
Medulloblatoma 
Glioblastoma multiforme 
 
Gorlin PTCH 9q31 Medulloblastoma 
Li- Fraumeni P53 17P13 Astrocytoma PNET 
 
CLASSIFICATION OF CNS TUMORS 
   The first comprehensive classification of CNS tumors formulated by Percival 
Bailey and Harvey Cushing in 1926 was based on the embryology and histology 
of the neoplastic cells117. Russel and Rubinstein continued to modify and update 
previous systems. The WHO classification 2007 edited by Dr. Oghagi and 
Dr.Louis is currently in use widely.51 WHO classifies CNS tumors into tumors 
of the neuroepithelial tissue that include astrocytomas, oligodendrogliomas, 
ependymomas and medulloblastomas, the tumors of the meninges, tumors of the  
cranial and paraspinal nerves , lymphomas, and hematopoietic neoplasms, germ 
cell tumors, tumors of the sellar region and metastatic tumors. 
GRADING SYSTEMS 
Grading of the CNS tumors are done to represent the nature of the tumor and 
therefore predict the patient survival. This is particularly useful for 
astrocytomas that have different treatment protocols for various grades. 
Previously, St. Anne Mayo system was used based on the four criteria of atypia 
of the nucleus, mitosis, microvascular proliferation and necrosis. The WHO also 
considers the above criteria but designates different terminologies for the 
tumors. Starting with the most benign as grade I, numerical grades II, III,IV 
represent increasing malignancy. Numerical grades assigned by the WHO are 
used in this dissertation.  There are definitive  criteria for grading most of the 
CNS neoplasms according to the WHO,  in particular for astrocytomas, 
meningiomas and oligodendrogliomas and epedymomas.  
GLIOMAS 
Glioma is a term that embraces astrocytomas, ependymomas and 
oligodendrogliomas. Astrocytomas are heterogenous neoplasms with various 
subtypes116 
ASTROCYTOMA:WHO grading and criteria for astrocytomas. 
WHO 
grade WHO designation Histological criteria 
I Pilocytic astrocytoma 
Circumscribed, biphasic: bipolar piloid 
cells;microcysts, Rosental fiblres ,rare mitotic 
figures,vascular proliferation or focal necrosis 
II Diffuse astrocytoma 
Moderate hypercellularity of monotonous 
cells; mild nuclear atypia; no or minimal 
mitotic activity 
III Anaplastic astrocytoma 
Increased cellularity and diffuse infiltration ; 
increased nuclear atypia; increased mitotic 
activity  increased 
IV Glioblastoma 
multiforme 
Vascular proliferation or necrosis; crowded 
anaplastic cells; marked nuclear atypia; brisk 
mitotic activity. 
 
 
PILOCYTIC ASTROCYTOMA: 
Pilocytic Astrocytoma  is a grade I tumor that accounts for 2% of all CNS 
tumors they are more common in children and accounts for 85% of cerebellar 
astrocytomas 
Gross: cystic and well demarcated. May appear spongy because of microcysts 
Microscopy : It has a biphasic dense and loose appearance. Piloid astrocytes 
with long hair like processes are characteristic. Though not diagnostic 
Rosenthal fibres and PAS positive eosinophilic granular bodies are seen in most 
cases. It has a good prognosis. Rosenthal fibres are highly eosinophilic, hyaline 
structures. They are round, oval or beaded with slightly irregular margins 
resembling cracked glass, resulting from their formation within glial process. 
They contain ubiquinated alpha B – crystalline which can be identified by IHC.  
Eosinophilic granular bodies consist of droplets of protein sometimes found in  
association with Rosentahl fibres. These protein droplets are bright pink and are 
PAS positive and can be stained with alpha 1- antichymotrypsin. 
PILOMYXOID ASTROCYTOMA:  
 They are similar to pilocytic astrocytoma and are typically found in very young 
children . It has bipolar cells that clusters around blood vessels, but its 
parenchyma is more pilocytic than ependymomatous. It also characteristically 
has a mucinous matrix.  CSF spread and local recurrences are more common. 
PXA is considered a grade II tumor according to the WHO. 
DIFFUSE ASTROCYTOMA: There are three distinct variants of astrocytoma 
1. Fribrillary astrocytoma: They are most common tumors in the 
cerebral hemispheres. When occurs in the brain stem they are associated 
with poor prognosis5 
Gross: mass lesion in the gray or white matter with indistinct boundaries 
Microscopy: Hypercellular tumor, and has an infiltrating borders with 
hyperchromatic oval to spindle nucleus. Presence of mild to moderate 
atypia. 
2. Gemistocytic astrocytoma: Gemistocytes are neoplatic astrocytes 
with a round hyperchromatic nucleus and a eccentrically placed hyaline 
pink cytoplasm packed with GFAP fibrils. Tihan et al113 has said 
neoplastic gemistocytes should comprise approximately 20% of the 
neoplasm. They have a male predominance and occur exclusively in the 
supratentorial compartment. They are clinically aggressive tumors and 
progress to high grade astrocytomas. The differential diagnosis for 
gemistocytes are the minigemistocytes of oligodendroglioma, reactive 
astrocytes and gangliogliomas. 
3. Protoplasmic astrocytoma: this tumor has overlapping features with 
pilomyxoid astrocytomas and oligoastrocytoma. They are composed of 
tumor cells with oval, hyperchromatic nucleus and thin wispy processes 
creating a cob web like growth pattern. 
ANAPLASTIC ASTROCYTOMA: 
The most common age group of occurrence is the fourth decade.  
Gross: Solid tumor exhibiting friable gray granular tumor tissue merging with 
the surrounding brain marked enlargement of gyri and basal ganglia. 
Microscopy : presence of increased cellular density. and increased mitosis. But 
absence of microvascular proliferation and necrosis is the characteristic of this 
grade of astrocytoma. Rule of thumb for evaluating cellular density is that  
the average distance between a nucleus and its nearest cell should not be less 
than the average nuclear diameter according to Johan M Kros46  
Average survival of patients with anaplastic astrocytoma is around 2 
years. Rarely anaplastic astrocytomas are associated with hereditary colonic 
polyposis or neurofibromatosis. 
 
 
 
GLIOBLASTOMA MULTIFORME: 
It represents one quarter of all adult gliomas and constitutes about 15% of 
pediatric gliomas. They are most often centered in the white matter. Peak age of 
occurrence is in the fifth decade. A cerebellar glioblastoma is very rare in all 
age groups. A denovo GBM occur as a result of EGFR amplification. Secondary 
GBM occur as a result of progression from a low grade astrocytoma according 
to Taiichi Saito et al112 
Gross : Poorly delineated mass, has a variegated appearance with areas of 
haemorrhage and necrosis. Multifocal occurrence is common. Blurred tumor- 
brain interface and gray- white matter junction commonly occurs. 
Microscopy: Markedly cellular  tumor composed of highly anaplastic  cells 
with significant nuclear pleomorphism. Vascular proliferation, mitotic activity 
and necrosis with or without pseudo pallisading tumor cells are features. 
 GLIOSARCOMA: 
It is a high grade glioma and a variant of GBM. According to Gilanis et al 34It 
accounts for < 2% of all gliomas and 5 % of astrocytomas. They have both 
astrocytic and sarcomatous components. They represent a mesenchymal 
metaplasia in the glioma. The sarcomatous element is usually a fibrosarcoma or  
MFH. The sarcomatous element do not stain with GFAP but stain with reticulin 
stain.  
Genetically the gliosarcomas are similar to  primary GBM except that they have 
not been shown to have amplifications of EGFR.92  
GLIOMATOSIS CEREBRI: 
Diffuse growth pattern where neoplastic glia spread widely throughout the brain 
frequently involving  more than two lobes and is frequently bilateral. 
Involvement of thalamus and basal ganglia is common. Bilateral  tumors with 
thalamus and basal ganglia involvement is common according to Lopes MBS et 
al58 
SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) 
It is a benign intraventricular tumor nearly exclusively occurring in the setting 
of tuberous sclerosis. Tuberous sclerosis is an autosomal dominant syndrome 
that causes hamartomatous neoplasms. It is associated with mutations in the 
TSC 1  and TSC 2  gene on chromosome 9 and 16 respectively. These tumor  
suppressor genes produce protein hamartin and tuberin.  It is typically located in 
the lateral or third ventricle. Mostly occurs in the children and young adults and 
accounts for less than 1% of the intracranial tumors. 
Gross: Solid, well demarcated often calcified tumor. ‘Candle guttering’ 
represent small wax dripping like appearance within the ventricle. 
Microscopy: Epithelioid, gemistocyte like or spindle cells arranged in sweeping 
fascisle, dysmorphic cells with neuron like nucleolus. Perivascular 
pseudorosettes are common. 
PLEOMORPHIC XANTHOASTROCYTOMA: 
PXA is a specialised variant of astrocytoma with predilection for the superficial 
cortex occurs mostly in children. 
Gross: Well demarcated, solid and rubbery consistency. Cystic components and 
calcifications are common. 
Microscopy: They are characterised by foci of pleomorphic astrocytes and 
spindled mesenchymal like cells arranged in fascicles or a storiform pattern. 
Multinucleated cells are common. Lipidized astrocytes (xanthoastrocytes) are 
seen in one fourth of cases. Rosenthal fibres and eosinophilic granular bodies   
may be seen occasionally. Astrocytes are confirmed by the strong GFAP 
positivity. These cells are surrounded by reticulin fibres. 
ASTROBLASTOMA: 
It is a rare cerebral glioma of unknown histiogenesis. It occurs  in children. 
Gross: solid and relatively well demarcated, may be cystic or necrotic. 
Microscopy: It has mixed astrocytoma and ependymoma like features. Grow in 
a circumscribed fashion and have perivascular pseudorosette. The perivascular 
GFAP rich cytoplasmic processes are broad and stout than that in ependymomas 
and remain thick throughout the entire thickness from cell body to adventitia of 
the vessel. There is extensive vascular hyalinisation. Astrocytomas may express 
focal GFAP, they do not stain with PTAH. This may be due to the expression of 
a non fibrillar form of GFAP molecule. 
OLIGODENDROGLIOMA:  
They represent the second major category of diffuse glioma with an incidence 
of  5 -15%. With an annual incidence of 0.5 per 100000 person years. 
(CBTRUS)14 They typically affect middle aged adults( 40- 45 years). Common 
in the frontal lobe. It is  more common in males according Mork et al73 . 50-90% 
cases show co-deletion of 1p and 19 q according to the study of Louis et al59 
Gross: borders are ill defined  with blurring of gray- white matter interface, 
calcification, cystic degeneration and hemorrhage are present. WHO criteria for 
grading of oligodendrogliomas is shown below. 
Grade Nomenclature Histological features 
II Oligodendroglioma 
Moderate cellularity; homogeneously round 
nuclei, “fried egg” halo   (paraffin sections); 
fine capillary network; mineralisation 
(microcalcifications) 
III Anaplastic 
oligodendroglioma 
Increased cellularity; high mitotic rate; marked 
cytologic atypia; microvascular proliferation 
 
Microscopy: Tumor is composed uniformly round to oval nuclei with bland 
chromatin and often small nucleoli and. Clear perinuclear halos impart a ‘fried 
egg’ appearance and occur as a result of formalin fixation artefact. Rich 
branching capillary network resembling ‘chicken wire’ are seen. Anaplastic 
oligodendrogliomas have frequent mitosis, endothelial hyperplasia, increased 
pleomorphism and epithelioid cytology. 
OLIGOASTROCYTOMA: 
Gross: well defined soft masses of greyish colour. Mucoid degeneration, 
calcification and cystic change are often present. 
Microscopy: Tumor is composed of mixture of two distinct neoplastic cell types 
with microcalcification and microcystic degeneration. It may be divided into 
biphasic of intermingled variants. It is important to differentiate between 
oligoastrocytomas and pure astrocytomas as oligoastrocytomas respond well to 
polychemotherapy. 
EPENDYMOMA:  
It accounts for 3- 5% of all brain tumors  and third most common cns tumor in 
children. Commonly occurs in the infratentorial region. 10 % occurs in the 
spinal cord but can occur within the cerebral hemispheres according to Figerella 
et al33  They are rare after 35 year according to CBTRUS12 
Gross: Well demarcated, soft, grayish red tumor, necrosis and hemorrhage is 
present. In the spinal cord it is well defined and homogenous. 
Microscopy: Moderately cellular gliomas with a monomorphic cells with round 
to oval nuclei with small nucleoli. Main histological features are perivascular  
pseudorosette, ependymal rosettes. 
Variants: Cellular ependymoma, papillary ependymoma, clear cell 
ependymoma, tanycytic ependymoma and myxopapillary ependymoma. 
World Health Organisation criteria for grading of ependymomas 
GRADE HISTOLOGIC FEATURES 
I 
Low proliferative potential, discrete . Possibility of cure after 
surgical resection alone. 
II 
Infiltrating tumor mass, low mitotic activity. Recurrence is 
common and tend to progress to higher grades of malignancy 
III 
Increased mitotic activity, highly infiltrative and features of 
anaplasia. 
IV Mitotically active, massive areas of necrosis 
 
Myxopapillary ependymoma occurs exclusively in the region of the filum 
terminale, cauda equine , sacrum and extravertebral soft tissues.they have both 
fibrillar and epithelial cells. Prominent vascular hyalinisation and perivascular 
mucoid degeneration are characteristic features. Kliehues P et al52 differential 
diagnosis may be chordoma and fibrous meningioma and schwannoma. 
Other low grade ependymomas are epithelioid ependymomas, papillary 
ependymoma, tanycytic ependymoma. 
Grade IV ependymoma ( Ependymoblastoma):  
It is characterised by conspicuous hypercellularity and ependymal rosettes. It is 
sometimes included under embryonal tumors . most cases occur in infants and 
children. It lacks the multinucleation and giant cells and has little or no 
endothelial proliferation. They infiltrate the leptomeninges and spread along the 
CSF.  
NEURONAL TUMORS: 
GANGLIOGLIOMA/GANGLIOCYTOMA: They are composed of intimately 
admixed neuronal and glial component and account for about 1% of all CNS 
tumors.  The usual site for ganglioglioma is the temporal lobe accounting for 
over one third cases  according to Blumke et al 7. The Peak age of occurrence is 
between the 2 nd – 3rd decade.  There is a male predominance according to 
Johnson JH et al 48 Gangliocytoma shows irregular groups of large multipolar 
neurons that shows dysplastic features. Stroma shows reactive glial cells and 
network of reticulin fibres. 
DESMOPLASTIC INFANTILE GANGLIOGLIOMA: 
Gross: Large tumor involving superficial cortex and leptomeninges. 
Microscopy:  It has a  desmoplastic stroma with entrapped astrocytes and or 
neuronal cells. 
DYSEMBRYPLASTIC NEUROEPITHELIAL TUMOR: 
Gross: Intracortical multinodular firm mass 
Microscopy: Typical glioneuronal element comprising microcystic spaces, 
oligodendrocyte like cells and floating neurons often associated with cortical 
dysplasias. 
CENTRAL NEUROCYTOMA: 
Gross:Greyish friable intraventricular tumor  with calcified areas. 
Microscopy: Composed of small regular polyhedral cells with honey comb like 
arrangement, round regular nucleus and pale cytoplasm. Microcalcifications are 
common. 
CHOROID PLEXUS PAPILLOMA: 
Gross: Circumscribed cauliflower like masses adherent to the ventricular wall 
but are well demarcated from the brain tissue  
Microscopy: Well differentiated papillary neoplasm lined by cuboidal cells 
arranged in a single layer on the delicate papillary fronds. No mitosis is seen. 
 
CHOROID PLEXUS CARCINOMA: 
Gross: Solid invasive tumor with hemorrhage and necrosis. 
Microscopy: Dysplastic cytological features include increased nuclear 
cytoplasmic ratio, mitotic activity, pseudostratified appearance and loss of 
nuclear polarity, cellular invasion into cerebral parenchyma with sheet like 
growth pattern. 
CHOROID GLIOMA OF THE THIRD VENTRICLE: 
Microscopy: Tumor is composed of clusters and cord of epithelial cells within a 
mucinous stroma. Stroma contain lymphoplasmacytic infiltration. 
PINEAL TUMORS: 
PINEOBLASTOMA: 
Gross: Soft friable, poorly demarcated tumor with hemorrhage and or necrosis. 
Microscopy:  it is composed of patternless sheets of densely packed small cels 
with round to regular nuclei and scant cytoplasm. Homer Wright and Flexner 
Wintersteiner rosettes may be seen. 
PINEOCYTOMA: 
Gross: well circumscribed lesion, gray tan in colour. 
Microscopy: composed of small uniform mature cells resembling pineocytes. 
Large pineocytomatous rosettes composed of abundant delicate tumor processes 
are seen. 
EMBRYONAL TUMORS: 
MEDULLOBLASTOMA: 
Most common pediatric brain tumor of the posterior fossa.  Mean age of 
occurrence  is  7- 8 years. The male to female ratio is 1.5: 1 according to  
Roberts et al95 
Gross: circumscribed, firm discrete mass 
Microscopy: Densely packed cells with round to oval or carrot shaped 
hyperchromatic nuclei surrounded by scanty cytoplasm. Neuroblastic rosettes 
which consists of tumor cells arranged in a circular fashion around  tangled  
cytoplasmic processes are typical. Seeding of the CSF commonly give rise to 
drop metastasis in the lumbosacral  spinal cord. 
Variants: Desmoplastic/ nodular medulloblastoma, medulloblastoma with 
extensive nodularity , anaplastic medulloblastoma, large cell medulloblastoma.  
ATYPICAL RHABDOID / RHABDOID TERATOID TUMOR: 
 It is grade IV tumor occurring in infants and young children < 3 years.  
Gross: large cystic and hemorrhagic tumor. 
Microscopy: Presence of rhabdoid cells with eccentrically placed vesicular 
nucleus, prominent nucleoli and globular eosinophilic paranuclear inclusions.25 
TUMORS OF THE CRANIAL AND PARASPINAL NERVES: 
SCHWANNOMA: 
Bilateral schwannomas are associated with Neurofibroma -2. They are 
encapsulated tumors commonly occurs in the cerebello-pontine angle. When 
they are attached to the eighth cranial nerve the term acoustic neuroma is used.  
Microscopy: they are composed of Schwann cells with characteristic  densely 
cellular Antoni A areas with nuclear pallisading and verrocay bodies and 
hypocellular Antoni B areas. 
NEUROFIBROMA: 
NF arise and infiltrate within nerves and thus the neoplastic cells are intimately 
admixed with axons. Schwann cell, perineural cells, fibroblasts and mast cells 
are also found. There vessels are typically thin walled with a myxoid 
extracellular matrix. 
MALIGNANT PERIPHERAL NERVE SHEATH TUMOR: 
It  has a very rare intracranial occurrence. They usually arise from a 
neurofibroma.tumar shows marked hypercellularity of spindle shaped cells with 
tapered ends, nuclear pleomorphism and abnormal mitosis. Necrosis indicates 
grade IV  tumor. Grade II tumor mimic neurofibroma but nuclei are darker and 
three times larger in size. S100 protein expression is markedly reduced.25 
MENINGIOMA: 
Meningiomas are tumors that arise from the leptomeningeal coverings of the 
brain and the spinal cord accounting for about 15 -20 % of all CNS tumors. 
there is a female preponderance98. Majority arise from the convexities and in the 
parasagittal location.Meningiomas are graded by the WHO into the following  
three grades . 
 
Malignant meningiomas tend to recur after complete resection at a much higher 
rate (70% within 8 years). The extent of surgical resection is a critical 
determinant of survival. Extracranial metastasis from meningioma is rare(0.1%) 
GRADE I GRADE II GRADE III 
0-3 mitosis / 10 hpf 
2 or fewer atypical 
histological features 
4-19 mitosis/10 hpf (or) 
≥ 3 foci of necrosis 
Macronucleoli 
Loss of architecture 
Small cell change 
Hypercellularity ( or) 
Brain invasion ( or)  
Clear cell or chordoid pattern. 
≥ 20 mitosis/10 hpf (or) 
papillary or rhabdoid 
pattern or otherwise overtly 
sarcoma or carcinoma like. 
but occur more frequently (30%)  in papillary meningioma according to 
Mathew JR et al65.  
Benign meningioma:grade I 
Gross: Spherical, lobulated firm and rubbery, usually well circumscribed dural 
based tumor. Tumors of the sphenoid wing grows as a flat carpet like masses 
termed ‘en plaque meningioma’  
Microscopy: Tumor cells form lobules which are surrounded by thin 
collagenous septae. Cells are uniform with oval nuclei, even chromatin and 
eosinophilic cytoplasm forming syncytium. 
Variants: Meningothelial, transitional, fibroblastic, psammomatous, 
angiomatous, microcystic, secretory, lymphoplasmacyte rich, metaplastic (bone, 
cartilage,xanthomatous, myxoid,fat etc) 
Atypical meningioma: grade II 
Gross: large tumor with cystic change 
Microscopy: Sheeting pattern of tumor cells, brain invasion, necrosis, nuclear 
pleomorphism, prominent nucleoli and increased mitotic activity are features. 
Variants: Chordoid and clear cell meningioma 
Malignant meningioma: grade III 
Microscopy: Features similar to atypical meningioma but with more marked 
mitotic activity. 
Variants: rhabdoid meningioma, papillary meningioma  
 Rhabdoid meningioma(RM) : It was first described in 1998 as an unusual 
variant of meningiomas. It has an increased proliferative activity and is 
classified as a WHO grade III meningioma.  According to the literature, most 
RMs behave aggressively and have a very poor prognosis according to Perry A 
et al 82 It is important to recognize rhabdoid morphology in a meningioma early 
to help in both the diagnosis and understanding of its clinical course. The 
characteristic cytological appearance is the presence of eccentric lightly 
eosinophilic spherical cytoplasmic inclusions that compress the nucleus against 
the plasma membrane . The inclusion are composed of whorled aggregates of 
intermediate filaments.82 
HEMANGIOPERICYTOMA: 
Gross: solid well demarcated tumor, tendency to bleed during surgery, cut 
surface is fleshy greyish to red brown. 
Microscopy: Highly  monotonous cellular tumor composed of plump cells with 
scant cytoplasm accompanied by numerous small vascular spaces and dense 
network of reticulin fibres. 
HEMANGIOBLASTOMA: 
It  often occurs in the setting of an inherited tumor predisposition syndrome 
with approximately 40 % of patients expressing features of von Hippel-Lindau 
(VHL) syndrome according to Convay et al19 and Boughey AM et al.8 It 
commonly arises from the cerebellum and occurs more commonly in males in 
the second decade according to Silver ML et al.108 
Gross:  It is a sharply circumscribed tumor with a reddish brown to yellow 
colouration reflecting the rich vasculature and high lipid content according to 
Edward Hard et al29 
Microscopy: Neoplastic elements are the stromal cells that have pale cytoplasm 
(neutral fat ) with vacuolated appearance and are found in the interstices  
between the ramifying vascular channels. 
MALIGNANT LYMPHOMA: 
Gross: single or  multiple masses in the cerebrum, firm friable gray yellow with 
central necrosis. 
Microscopy: lymphoma that diffusely infiltrates the brain parenchyma in the 
angiocentric pattern forming collar of tumor cells within concentric perivascular 
reticulin deposits. 
Variants: B cell lymphoma, T cell lymphoma, Hodgkin disease, MALT 
lymphoma of the dura. 
PRIMARY CNS LYMPHOMA: 
It accounts for 2% of extranodal lymphomas and 1 % of intracranial tumors 
according to Robins and Cotran96. It occurs commonly in the 
immunosuppressed individuals including those with AIDS, after transplants. 
They are mostly of the B cell origin. They are multifocal  and relatively well 
defined in the brain parenchyma. 
Microscopy: diffuse large cell lymphomas are the most common histological 
group. The tumor cells accumulate around the blood vessels. Reticulin stains 
shows the characteristic ‘hooping’ pattern with silver stains around individual 
tumor cells 
GERM CELL TUMORS: 
They are derived from primordial germ cells that migrate to the central neuraxis 
from the fetal yolk sac. 
Germinoma: Gross: solid soft, friable tumor 
Microscopy: Histologically similar to seminoma of the testis. They are 
composed of uniform cells resembling primitive germ cells with large vesicular 
nuclei, prominent nucleoli and lymphoplasmacytic cellular infiltrates. These 
tumors are PLAP ( Placental alkaline phosphatase) positive but not α- 
fetoprotien or β- HCG. 
Teratoma: 
Gross: mucous laden cysts, fat, chondroid nodules or bony spicules, rarely well 
fromed hair or teeth. 
Mature teratoma: 
Composed of fully differentiated adult type tissue elements arranged in a pattern 
resembling normal tissue. 
Immature teratoma:  
Composed of incompletely differentiated components resemling fetal tissues. 
Yolk sac tumor: 
Composed of primitive appearing epithelial cells set in a loose, variably cellular 
and myxoid matrix resembling extraembryonic mesoblast. Eosinophilic hyaline 
globules may be seen occasionally 
Embryonal carcinoma: 
Composed of large cells that proliferate in cohesive sheets and nests, form 
abortive papillae or gland like spaces. Tumor cells replicate the structure of the 
early embryo forming embryoid bodies 
Choriocarcinoma: 
Gross: Extensive hemorrhagic and necrotic tissue 
Microscopy: Characterised by extra-embryonic differentiation along the 
trophoblast. Diagnosis requires the identification of cytotrophoblastic elements 
and syncytiotrophoblastic giant cells. 
TUMORS OF THE SELLAR REGION: 
CRANIOPHARYNGIOMA: 
Gross: Well demarcated solid tumor with cystic component, calcification. Cyst 
contains cholesterol rich, machine oil like, thick brownish yellow fluid. 
Microscopy: Consists of strands of ameloblastic epithelium with peripheral 
palisading of nuclei. Diagnostic features are nodules of compact keratin and 
dystrophic calcification 
PITUITARY ADENOMA: 
Gross:  well circumscribed soft tumor. Grey to yellow homogenous or 
granular.based on the size the adenomas are classified into microadenomas(<1 
cm), macroadenomas (> 1 cm)and giant adenomas (>5 cm) according to Chako  
G et al 15 
Microscopy: There are two core features to distinguish adenomas from normal 
pituitary tissue are the  loss of regular acinar pattern and cellular homogeneity 
according to De Lilleis23. The WHO categorises adenomas primarily by IHC 
staining for hormone products. The two features to distinguish adenomas from 
normal pituitary tissue are the absence of the regular acinar architecture and 
cellular homogeneity the ususal patterns of a pituitary adenoma are a sheet like 
pattern, trabecular, papillary, oncocytic, nested, ribboned, spindled or fascicular.  
The clinical presentation of prolactinomas is sexually dimorphic with 
females presenting at younger ages with microadenomas (<1cm )  as they have 
a prolactin responsive breast and endometrial tissue, whereas males present at 
an older age  with macroadenomas (>1 cm) 
 
METASTATIC TUMORS: 
They are the most common neoplasms accounting for more cases than the 
primary tumors according to Walker et al121. All metastasis reach the CNS by 
hematogenous route according to Gavriloc et al35. Most common primary tumor 
to metastasise to the CNS  are from the lungs and the breast as per the study of 
Lagerward et al 55 
Primary tumor Frequency of metastasis to brain 
Lung 26%- 42% 
Breast 15%-25% 
Skin ( melanoma) 39% -92% 
Kidney 10%- 25% 
Gastrointestinal tract 5% -7% 
 
Gross:  Occur as discrete round or well circumscribed grey white or tan masses. 
Tumor may be attached to the dura or leptomeninges and may form  nodules. 
Microscopy: metastasis are similar to those of the primary tumor from which 
they arise. Tumor necrosis is frequent with well defined borders with the 
adjacent parenchyma and displace rather than infiltrating the tissue as they 
enlarge. 
 
 
IMMUNOHISTOCHEMISTRY:  
Ki- 67: 
Various indices of cellular proliferative activity have been investigated. 
Mitotic counts only detect cells in the M phase, are dependent on the period of 
time between surgical removal and fixation of the specimen, and suffer from 
heterogeneous distribution and confusion between mitoses and nuclear pyknosis 
and karyorrhexis10.  
Counting nucleolar organiser regions (AgNORs) and 5-
bromodeoxyuridine or tritiated thymidine labelling are also not practical in a 
routine situation. Bromodeoxyuridine ( BUdR) as a marker of tumor cell S 
phase fraction. BUdR fell out of favour because it required either injecting the 
patients with the compound prior to surgery or incubating a fresh tissue in 
BUdR containing solution immediadely upon removal. When Ki-67 labelling 
was developed it quickly took over the standard diagnostic role in determining  
proliferation potential in the tumor 
 Ki-67 recognises a proliferation specific nuclear antigen. The Ki-67 
protein is a nuclear protein doublet, 345-395 kDa, playing a pivotal role in 
maintaining cell proliferation. Ki-67 is present in all non-G0 phases of the cell 
cycle. ‘Ki’  indicated the place of its origin- Kiel a town in Germany and 67 
stands for the number of the clone of mouse antibody out of the  96 that was 
isolated.  Beginning in the mid G1, the level increases through S and G2 to 
reach a peak in M. In the end of M, is is rapidly catabolized.  
The Ki-67 labelling index (LI), i.e., the percentage of cells in a tissue 
staining for Ki-67, indicates the growth fraction. . There is a potential interest in 
using this marker in routine histopathology because it is simple and more rapid 
than the classic methods of evaluation of proliferating cells.  
 Grading of brain tumors are based on the observation of mitosis. The 
greatest disadvantage is that the brain biopsy material is often very  minimal 
and moreover may not be representative in most cases. Also crush artefacts may 
mimic mitosis in the sections. So a valid marker to highlight the exact number 
of cells undergoing mitosis is necessary and Ki -67 has proven to be the best 
immune marker in this study. 
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OBSERVATIONS AND RESULTS 
INCIDENCE: 
During the study period between January 2010 to May 2012, a total of 11050 
general biopsy material were received in the department of pathology at 
Thanjavur medical college and Hospital Thanjavur. 100 central nervous system 
tumors were included in the study with an average  incidence of 8.19% (chart 1) 
Table -1  Incidence of CNS neoplasms in our study 
 
 
 
 
 
 
 
 
 
Incidence of various CNS neoplasms in our study is shown in Table – 2 
(chart –2)  out of the 100 cases of CNS neoplasms, astrocytomas are the most 
common neoplasm constituting about 45% of cases, followed by meningiomas 
(23%), nerve sheath tumors (13 %),medulloblastoma(7 %) followed by pituitary 
adenomas constituting about 4 % . Ependymomas and hemangioblastomas, and 
secondary metastatic deposits constituted about 2% each and ganglioglioma and 
oligodendroglioma occurred in 1% of the total cases.  
 
Period Total no of 
specimens 
Total 
neoplams 
Total CNS 
neoplasms 
Incidence 
Jan 2010-Dec 
2010 
4556 1520 47 3.09% 
Jan 2011- Dec 
2011 
4840 1380 35 2.5% 
Jan 2012- May 
2012 
1654 690 18 2.6% 
Total 11050 3590 100 8.19 % 
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           Table 2 
    Age wise incidence of CNS neoplasms 
Tumor 1-10 
yrs 
11-20 
yrs 
21-30 
yrs 
31-40 
yrs 
41-50 
yrs 
51-60 
yrs 
61-70 
yrs 
71-80 
yrs 
Total  
Astrocytoma 
- 4 10 11 11 7 1 1 45 
Meningioma 1 - 2 7 4 5 3 1 23 
Nerve sheath 
tumor 
1 2 2 3 3 1 1 - 13 
Medulloblastoma 3 4 - - - - - - 7 
Pituitary 
adenoma 
1 - - 2 - - 1 - 4 
Ependymoma 
- - - 1 - 1 - - 2 
Hemangioblasto
ma 
- - 1 - 1 - - - 2 
Metastasis 
- - - 1 1 - - - 2 
Ganglioglioma 
- - - - 1 - - - 1 
Oligodendroglio
ma 
- - 1 - - - - - 1 
Total 6 10 16 25 21 15 6 2 100 
 
Table 2 also shows the age wise incidence of CNS neoplasms. In 
the age group of 1-10 yrs medulloblastoma is the most common 
neoplasm. Astrocytomas are common in the  fourth and the fifth decade 
(49%). Meningiomas are also common in the fourth decade (30%). In this 
study more number of medulloblastomas occurred  in the second 
decade(57%). 
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                                                Table -3 
                  Overall sites of occurrence of CNS neoplasms 
 
 
 
 
 
 
 
From the above table -3 (chart -3) we observe that the most common site 
of occurrence of CNS tumors is in the frontal lobe (28%)  followed by the 
parietal lobe(23%) 
                                               Table – 4 
                      Age and sex wise incidence of CNS tumors 
 
 
 
 
 
 
 
 
 
Site No. Of cases Percentage 
Frontal lobe 28 28% 
Parietal lobe 23 23% 
Temporal lobe 13 13% 
Spinal  cord 11 11% 
Posterior fossa 8 8% 
CP angle 6 6% 
Pituitary fossa 5 5% 
Sphenoid wing 3 3% 
Occipital lobe 3 3% 
Age Male Female Total 
1-10 yrs 2 4 6 
11-20 yrs 7 3 10 
21-30 yrs 9 7 16 
31-40 yrs 10 14 24 
41-50 yrs 13 7 20 
51-60 yrs 7 8 15 
61-70 yrs 5 2 7 
71-80 yrs 1 1 2 
Total 54 46 100 
CHART- 3 
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 Table-4 (chart 4) shows that most common age group of 
occurrence of CNS tumors were in the age group of 31- 40 years(24%) 
followed by 41-50 years age group. Least number of cases occurred in the 
70 -80 years age group (2%) followed by 1-10 years age group (6%). 
There was a definite overall male preponderance( 54 %) in our study. 
GRADING 
 
Grading is done for all tumors according to the WHO 2007 norms. This 
includes  the neuroepithelial, meningeal, neural and pituitary tumors. The 
overall occurrence of various grades of neoplasm with respect to age is 
illustrated in the following table. 
Table-5 
WHO grading  of all CNS neoplasms with respect to age 
 
Grade 1-10 yrs 
11-20 
yrs 
21-30 
yrs 
31-40 
yrs 
41-50 
yrs 
51-60 
yrs 
61-70 
yrs 
71-80 
yrs 
Tota
l 
I 2 2 4 10 9 7 6 1 42 
II - - 3 6 2 2 - - 13 
III 1 1 6 4 1 3 1 - 16 
IV 3 7 3 3 8 4 - 1 29 
 
The above table -5 (chart -5) indicates that the grade I tumors are the 
most common  followed by grade IV tumors. Grade I and grade II tumors 
commonly occurred in the 31- 40 age group and grade IV tumors had a 
bimodal peak in the second and the fourth decade. 
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Table -6 
Grading and sex wise incidence of CNS neoplasms. 
 
Grade Male Percentage Female Percentage 
I 18 33% 24 53.3% 
II 9 16.98% 4 8.8% 
III 10 18.86% 6 13.3% 
IV 17 31.48% 12 26.08% 
Total 54 54.08% 46 45.91% 
 
Our study showed a overall increase in occurrence of the CNS tumors in 
the male population (54 %). The above table -6 (chart-6) shows that the 
females outnumber the males in the grade I tumors (24 cases,53.3%) 
alone. Grade II( 9 cases 16.98 %), grade III (10 cases, 18.86%) and grade 
IV (17 cases,31.48 %)  tumors are common in males.  
                           
    WHO grading for astrocytomas 
 Astrocytomas were graded according to the WHO criteria of cellularity, 
nuclear atypia, mitosis and microvascular proliferation/necrosis as showin 
the table -7 below 
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Table -7 
 
WHO grading of Astrocytoma 
 
S.no Pathology 
no 
HPE diagnosis Increased 
cellularity 
Nuclear 
atypia Mitosis 
Microvascular 
proliferation& 
necrosis 
Grade 
1 261/10 Glioblastoma 
multiforme + + + + IV 
2 326/10 Diffuse 
astrocytoma + + - - II 
3 433/10 Anaplastic 
astrocytoma + + + - III 
4 555/10 Anaplastic  
astrocytoma + + + - III 
5 881/10 Glioblastoma 
multiforme + + + + IV 
6 915/10 Glioblastoma 
multiforme + + + + IV 
7 1149/10 Glioblastoma 
multiforme + + + + IV 
8 1399/10 Diffuse 
astrocytoma + + - - II 
9 1437/10 Fibrillary 
astrocytoma + - - - I 
10 1621/10 Diffuse 
astrocytoma + + - - II 
11 1660/10 Diffuse 
astrocytoma + + - - II 
12 1831/10 Anaplastic 
astrocytoma + + + - III 
13 2141/10 Glioblastoma 
multiforme + + + + IV 
14 2236/10 Glioblastoma 
multiforme + + + + IV 
15 2307/10 Glioblastoma 
multiforme + + + + IV 
16 2401/10 Diffuse 
astrocytoma + + - - II 
17 2814/10 Diffuse 
astrocytoma + - - - I 
18 3683/10 Glioblastoma 
multiforme + + + + IV 
19 3686/10 Glioblastoma 
multiforme + + + + IV 
20 3990/10 Glioblastoma 
multiforme + + + + IV 
21 4128/10 Anaplastic 
astroctoma + + + - III 
22 233/11 Diffuse 
astrocytoma + + - - II 
23 272/11 Diffuse 
astrocytoma + + - - II 
24 504/11 Anaplstic 
astrocytoma + + + - III 
25 734/11 Glioblastoma 
multiforme + + + + IV 
26 1383/11 Glioblastoma 
multiforme + + + + IV 
27 1951/11 Anaplastic 
astrocytoma + + + - III 
28 2030/11 Anaplastic 
astrocytoma + + + - III 
29 2484/11 Diffuse 
astrocytoma + - - - I 
30 2630/11 Anaplastic 
astrocytoma + + + - III 
31 3523/11 Anaplastic 
astrocytoma + + + - III 
32 3730/11 Glioblastoma 
multiforme + + + + IV 
33 3841/11 Glioblastoma 
multiforme + + + + IV 
34 4327/11 Glioblastoma 
multiforme + + + + IV 
35 4535/11 Gliosarcoma + + + + IV 
36 215/12 Glioblastoma 
multiforme + + + + IV 
37 295/12 Diffuse 
astrocytoma + + - - II 
38 338/12 gliosarcoma + + + + IV 
39 539/12 Diffuse 
astrocytoma + + - - II 
40 628/12 Diffuse 
astrocytoma + + - - II 
41 819/12 Glioblastoma 
multiforme + + + + IV 
42 934/12 Anaplastic 
astrocytoma + + + - III 
43 1380/12 Anaplastic 
astrocytoma + + + - III 
44 1475/12 Anaplastic 
astrocytoma + + + - III 
45 1827/12 Glioblastoma 
multiforme + + + + IV 
 
All the astrocytomas were graded meticulously by light microscopy and 
classical features of Glioblastoma like glomeruloid endothelial proliferation and 
pseudopalisading necrosis were observed. 
 
                                                        
 
Table -8 
                Grade and sex wise incidence of astrocytoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The above  table-8 (chart-7) show that there is an male preponderance in 
all grades of astrocytomas . Also in this study a higher incidence of grade 
IV astrocytomas was noted (44 %) followed by grade III (27%), grade II 
(22%) and grade I (7%) asrocytoma (fig 2-5). Two cases of 
gliosarcoma(fig 6)  which is considered to be a variant of glioblastoma 
multiforme was included under grade IV astrocytoma 
 
 
 
 
 
Grade Male Female Total 
I 2 1 3  (7%) 
II 7 3 10 (22%) 
III 9 3 12 (27%) 
IV 11 9 20 (44%) 
Total 29 (64.4%) 16 (35.5%) 45 
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                                            Table – 9 
                Grade and age wise incidence of astrocytoma 
 
 
The above table- 9 (chart-8) shows that overall all grades of astrocytomas  
are common in the third and the fourth decade followed by second decade 
in our study. There were no cases in the first decade and just one case 
each in the sixth and the seventh decade.  
 
 
 
 
 
Grade 1-10 
yrs 
11-20 
yrs 
21-30 
yrs 
31-40 
yrs 
41-50 
yrs 
51-60 
yrs 
61-70 
yrs 
71-80 
yrs 
I - - - 3 1 - - - 
II - - 2 3 1 2 - - 
III - 1 5 1 2 2 1 - 
IV - 3 3 4 7 3 - 1 
Total 0 4 10 11 11 7 1 1 
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TABLE -10  
WHO grading of meningioma 
 
 
 
 
S.No Patho no. HPE diagnosis Increased 
cellularity 
Sheeting 
pattern 
Increased 
mitosis 
grading 
1. 263/10 Meningothelial meningioma N - - I 
2. 265/10 Transitional meningioma N - - I 
3 393/10 Transitional meningioma N - - I 
4 577/10 Anaplastic meningioma ↑ + >20/10 hpf III 
5 667/10 Meningothelial  meningioma N - - I 
6 1439/10 Meningothelial meningioma N - - I 
7. 1967/10 Anaplastic meningioma ↑ + >20/10 hpf III 
8 3353/10 Angiomatous meningioma N - - I 
9. 3741/10 Psammomatous meningioma N - - I 
10. 3822/10 Transitional meningioma N - - I 
11 4258/10 Meningothelial meningioma N - - I 
12. 834/11 Transitional meningioma N - - I 
13. 1561/11 Atypical meningioma ↑ + >4/10 hpf II 
14 1839/11 Transitional meningioma N - - I 
15 2771/11 Transitional meningioma N - - I 
16 2936/11 Meningothelial meningioma N - - I 
17 3380/11 Meningothelial meningioma N - - I 
18 3401/11 Meningothelial meningioma N - - I 
19 4113/11 angiomatous meningioma N - - I 
20 4670/11 Transitional meningioma N - - I 
21 299/12 Transitional meningioma N - - I 
22 909/12 Meningothelial meningioma N - - I 
23 1261/12 Rhabdoid meningioma ↑ + >20/10 hpf III 
Table -11 
Grade and sex wise incidence of  meningioma 
 
Grade Male Female Total 
I 2 17 19 (82%) 
II 1 - 1 (5%) 
III - 3 3 (13%) 
Total 3 (13%) 20(87%) 23 
 
The above table- 11( chart- 10) shows that there are about 87% of 
meningiomas occurring in females outnumbering the males(13%). Grade 
I tumors constitute about 18 cases(82 %) and grade III tumors occurring 
in 3 cases(13%) ( fig- 9,10) including a case of rhabdoid meningioma. 
(fig - 11)  
Table -12 
Grade and age of various meningiomas 
 
Age Grade I Grade II Grade III Total 
1-10 yrs - - 1 1 
11-20 yrs - - - - 
21-30 yrs 1 - 1 2 
31-40 yrs 4 1 1 6 
41-50 yrs 5 - - 5 
51-60 yrs 5 - - 5 
61-70 yrs 3 - - 3 
71-80yrs 1 - - 1 
Total 19(82.6%) 1(4.4%) 3(13%) 23 
 
Most common age group of occurrence of meningiomas were in the third 
decade( 6 cases) followed by fourth and fifth decade. There were no case 
in the 11-20 age group and only a single case occurred in the 1-10 yrs and 
71-80 yrs age group.  
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                                                  Table -13 
                              WHO grading of neural tumors 
   
Tumors of the cranial and spinal nerves constitute about 13% of cases in 
this study. Schwannomas are the commonly reported tumor(9 cases) 
followed by neurofibroma. Only one case of low grade MPNST was 
reported(fig- 17). Most of the tumors occurred in the cerebello- pontine 
angle (6 cases) and the remaining occurred in the spine.(chart -11) 
 
S.no Patho 
no. 
Age/
sex 
HPE 
diagnosis Site Mitosis Necrosis Grade 
1. 479/10 19/M Schwannoma D9-D10 - - I 
2. 1374/10 
48/F 
Schwannoma Cerebello-pontine angle - - I 
3. 3859/10 
38/F 
Schwannoma Cerebello-pontine angle - - I 
4. 4211/10 
42/M 
Schwannoma Cerebello-pontine angle - - I 
5. 100/11 65/M Schwannoma L3-L4 - - I 
6. 723/11 9/F Neurofibroma D1-D3 - - I 
7. 2032/11 26/M Neurofibroma C5-C6 - - I 
8. 2890/11 55/F Neurofibroma L1-L2 - - I 
9. 3055/11 35/F MPNST D1-D3   II 
10 3303/11 
30/M 
Schwannoma Cerebello-pontine angle - - I 
11 390/12 20/M Schwannoma D7-D8 - - I 
12. 500/12 
49/M 
Schwannoma Cerebello-pontine angle - - I 
13 1537/12 
40/M 
Schwannoma Cerebello-pontine angle - - I 
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 TABLE – 14 
Age wise incidence of neural tumors 
AGE IN YRS MALE FEMALE 
1-10 - 1 
11-20 2 - 
21-30 2 - 
31-40 1 2 
41-50 2 1 
51-60 1 - 
61-70 1 - 
Total 9 4 
 
        Also it is noted that the sex wise incidence is more favourable towards 
males ( 9 cases). The neural tumors had a wide distribution with respect to age 
with the maximum occurrence in the 30- 50 yrs age group. Most of the neural 
tumors occurred in the spinal cord except one case of meningioma and one case 
of myxopaillary ependymoma 
 
 
 
 
 
 PEDIATRIC BRAIN TUMORS 
TABLE 15 
Incidence of brain tumors in children 
s.no  Patho no Age/sex Histological diagnosis SITE grade 
1 478/10 16/M Medulloblastoma  Posterior fossa IV 
2 2487/10 7/M Medulloblastoma  posterior fosa IV 
3 2526/10 14/M Medulloblastoma Posterior fossa IV 
4 2738/10 11/M Medulloblastoma Posterior fossa IV 
5 3482/10 10/F  Medulloblastoma Posterior fossa IV 
6 3739/10 6/F Medulloblastoma Posterior fossa IV 
7 723/11 9/F Neurofibroma  D1-D3  I 
8 1167/11 12/M Medulloblastoma Posterior fossa IV 
9 1383/11 13/F GBM Frontal lobe IV 
0 4535/11 15/F Gliosarcoma  Frontal lobe IV 
11 338/11 15/F Gliosarcoma  Frontal lobe IV 
12 1261/12 10/F Rhabdoid meningioma Temporal lobe III 
 
Distribution of childhood brain tumors are shown in chart -
12.Medulloblstoma was the next common tumor reported. We had 7 cases ( 7%) 
(fig 16), all of them occurred in the pediatric age group ( 0-15 years). All  
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tumors were from the posterior fossa. Males ( 5 cases) outnumbered the 
females (2 cases).. 
There were four cases(4%) of pituitary adenoma (fig 13)in our study with 
equal male to female ratio. All the four cases occurs in the sellar region. Two 
cases were in the 30 -40 age group but the other two were in the extremes of 
age. One in a 10 yrs old girl and the other in a 70 years male.(chart -12) 
Two cases of ependymoma(2%) was reported(fig 18). One was a classical 
ependymoma in a 32 years male in the frontal lobe. Another was a case of 
myxopapillary ependymoma(fig 19) that occurred in the classical  lumbosacral 
location of a 55 years old man.  
There were two cases( 2%) of hemangioblastoma(fig 15) in our study. 
One tumor occurred in a 23 years old male in the posterior fossa. And the other 
was in a 65 years male in the parietal lobe which was a rare site. 
There was one case each of oligodendroglioma(fig 14) and ganglioglioma 
(fig 12) (1%). Oligodendroglioma was reported in a 30 years old male in the 
parietal region and ganglioglioma was reported in a 42 years old male from the 
frontal lobe. 
 In our study we had two cases(2%) of metastatic deposit(fig 20) in the brain.  
Both the cases were between 40 -45 years and were adenocarcinomatous 
deposits. The primary was found in the GIT for both cases 
IMMUNOHISTOCHEMISTRY 
TABLE – 16 
KI- 67 LABELLING INDEX OF VARIOUS CNS NEOPLASMS 
S.NO Patho no HPE Diagnosis MIB INDEX 
1. 2484/11 Astrocytoma – grade - I <1 % 
2. 272/11 Astrocytoma – grade -II 2 % 
3. 2630/11 Astrocytoma – grade III 50-60% 
4. 2307B/110 Astrocytoma – grade - IV 80% 
5. 4535/11 Gliosarcoma 60% 
6. 4258/10 Meningioma- grade - I 0.1% 
7. 1561/11 Meningioma- grade - II 8-10 % 
8. 1261/12 Meningioma- grade- III 
(Rhabdoid) 
20 % 
9. 217/12 Oligodendroglioma 0.5% 
10. 3929/11 Ganglioglioma Negative 
11. 1110/11 Medulloblastoma 5 % 
12. 2452/10 Pituitary adenoma Negative 
13. 1416/11 Hemangioblastoma <1 % 
14. 390/12 Schwannoma < 0.1% 
15. 1952/10 Ependymoma 1% 
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Table 16 (chart- 13) shows the expression of Ki -67 in various CNS neoplasms 
in this study.  Grade I and II astrocytomas showed a very low expression of the 
antigen (<1 % and 2%  respectively) ( fig- 21,22), indicating the low mitotic 
activity. Whereas the grade III and grade IV astrocytomas and gliosarcoma  
showed more than 50 % positivity.(fig – 23,24,25) Similarly in meningiomas as 
the grade increased a significant increase in the Ki 67 expression was observed 
with highest expression in rhabdoid meningioma -20%   ( grade III )  (fig- 28). 
There was very minimal expression of the antigen in grade I/II  meningioma of 
<0.1 %.(fig 26,27 ). Oligodendroglioma showed a labelling index of 0.5% (fig 
29). Medulloblastoma being a grade IV tumor showed an expression of  5 % 
(fig 30). Other low grade tumors like ependymoma (1%) (fig 35), 
hemangioblastoma (< 1% ) (fig 34) and schwannoma (<0.1%) (fig31) showed 
very little expression of Ki 67 indicating very low mitotic activity and less 
aggressive nature of these tumors. Ki 67 labelling index was negative in 
ganglioglioma and in pituitary adenoma.  
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Figure – 1 Gross specimen of  TRANSITIONAL MENINGIOMA showing a fairly 
circumscribed grey white fibrous mass with focal areas of haemorhage 
 
 
 
Figure- 2 PILOCYTIC ASTROCYTOMA GRADE –I numerous Rosenthal fibres lie 
among a delicate network of hair like cytoplasmic processes  H&E  
 (40 X) 
 
 
  
Figure- 3 ASTROCYTOMA GRADE –II. Cellular tumor containing large and 
hyperchromatic nuclei with irregular nuclear contours. H&E (40 X) 
                        
                        
                          
 
Figure- 4 ASTROCYTOMA GRADE –III  Cellular tumor exhibiting diffuse 
anaplasia,nuclear pleomorphism and increased mitosis H& E (40 X) 
 
 
  
Figure -5 ASTROCYTOMA GRADE –IV (GBM) -  pseudopallisading necrosis with  a 
rim of radially oriented cells around a hypocellular center with scattered pyknotic 
nuclear debris.  H&E (40 X) 
 
 
 
Figure -6 GLIOSARCOMA-biphasic tumor with spindle cells sarcomatous element and 
scattered islands of residual fibrillar pink astrocytoma  fascicles of spindle cells with 
mitosis H& E (40 X )  
 Figure -7 GLIOSARCOMA – GFAP immunostaining- showing cytoplasmic positivity in 
the glial cells and negative staining in the non glial area.  
 
 
  
 
 
Figure 8-  GLIOSARCOMA– Reticulin deposition is seen  around the  individual and 
small nests of tumor cells. Reticulin stain (40 X) 
 
 
  
Figure -9 PSAMMOMATOUS MENINGIOMA (GRADE – I) numerous whorls of  
meningothelial cells and formed lamellated spheres of  Psammoma bodies H& E (10 X) 
 
 
 
Figure -10  GRADE II MENINGIOMA showing loss of architecture, sheeting pattern 
and increased mitotic activity.  H& E (10 X ) 
 
 
  
Figure 11 RHABDOID MENINGIOMA GRADE -III - showing  rhabdoid cells with 
eccentric, eosinophilic, spherical,cytoplasmic inclusion compressing the nucleus against 
the plasma membrane- H&E (10 X) 
 
 
 
Figure – 12 GANGLIOGLIOMA- Biphasic tumor with a neoplastic  ganglion cell 
surrounded by glial cells- H& E (40 X) 
 
  
Figure -13 PITUITARY ADENOMA-  uniform small round cells with scanty  
eosinophilic cytoplasm H&E (40 X) 
 
 
 
Figure -14 OLIGODENDROGLIOMA- composed of uniform, round, regular nuclei 
surrounded by a clear cytoplasmic halo H&E (10 X ) 
 
  
Figure -15 HEMANGIOBLASTOMA- showing dense capillary meshwork and finely 
interspersed vacuolated stromal cells H& E (10 X) 
 
 
 
Figure – 16 MEDULLOBLASTOMA – poorly differentiated  sheets of cells with 
hyperchromatic nuclei  and minimal cytoplasm. Numerous mitotic figures are seen    
H& E (10 X) 
 
  
Figure -17 MPNST –long fascicles of malignant spindle cells with hyperchromatic, 
atypical  nuclei and increased mitotis H& E (10 X) 
 
 
 
Figure -18  EPENDYMOMA-  perivascular pseudorosette consisting of ependymal 
tumor cells oriented around a central blood vessel with long fibrillar processes that 
extend radially towards the vessel H & E (10 X) 
 
 
  
 
Figure -19  MYXOPAPILLARY EPENDYMOMA –microcystic appearance with pools 
of mucinous material among a monomorphic population of fibrillar glial cells  H & E 
(40 X) 
 
 
 
Figure -20 METASTATIC ADENOCARCINOMATOUS DEPOSIT.Gland spaces lined 
by malignant epithelial cells H & E (10 X) 
 
 
KI- 67 IMMUNOPROFILE OF CNS TUMORS 
 
 
 
Figure -21 ASTROCYTOMA GRADE –I,  Ki-67 labelling index- <1%, (10 
X) 
 
 
 
Figure -22 ASTROCYTOMA GRADE II- Ki67 labelling index -  5% (10 X) 
 
 
 
  
Figure -23 ASTROCYTOMA GRADE III Ki -67 labelling index – 50 % 
 (10 X) 
 
 
 
Figure – 24 ASTROCYTOMA GRADE IV, Ki-67 labelling index - > 80 % 
(10 X) 
 
 
 
 
  
Figure -25 GLIOSARCOMA , Ki-67 labelling index > 60%, (10 X) 
 
 
 
 
Figure -26 MENINGIOMA GRADE I , Ki -67 labelling index 1 % (40 X) 
 
 
 
 
 
 
  
Figure – 27 MENINGIOMA GRADE II, Ki-67 labelling index 10 % (10 X) 
 
 
 
 
Figure -28 MENINGIOMA  GRADE III, Ki- 67 labelling index 20 % 
 (10 X) 
 
 
 
 
  
Figure -29 OLIOGODENDROGLIOMA Ki -67 labelling index 0.5 %  
(10 X) 
 
 
 
 
Figure -30  MEDULLOBLASTOMA Ki-67 labelling index -5 % (40 x) 
 
 
 
 
  
Figure -31 SCHWANNOMA Ki-67 labelling index - <1 % (10 X) 
 
 
 
 
Figure -32 GANGLIOGLIOMA showing  negative Ki-67  immunoprofile 
(10 X )  
 
 
 
 
  
Figure -33  PITUITARY ADENOMA showing negative  Ki-67 
immunoprofile  (10 X ) 
 
 
 
Figure – 34 HEMANGIOBLASTOMA Ki-67 labelling index 1% (10 X) 
 
 
 
 
 
  
Figure -35 EPENDYMOMA , Ki-67 labelling index <1% (10 X) 
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 DISCUSSION: 
 The central nervous system tumors are the most widely classified of all 
the other tumors of major systems of the body, with around 86 major tumor 
types apart from their variants. The CNS tumors are always a cause of concern 
among histopathologists due to its wide variation in the morphology and also 
the difficulties faced in grading these tumors accurately.  
          In the present study about 100 CNS tumors, reported in the department of 
Pathology at TMC, were analysed. The incidence of CNS neoplasm during the 
time period between Jan 2010- May 2012  were found to be 8.19%. 
According to the data of the CBTRUS ( Central Brain Tumor Registry of 
the United States) 12  the overall rate of occurrence of CNS tumors is about 
19.34 per 100,000 person years. According to Chang Hyun et al16 it was 11.69 
per 100,000 person years. 
  There are many well established studies like that of Chang et al16  to 
prove that there are great variations in the occurrences of various CNS 
neoplasms according to the age gender, ethnicity and geography. In this study 
too there were a wide variation in the distribution of tumors according to age, 
sex and location. Most commonly the CNS tumors occurred in the age group of 
31 -40 years (24%) followed by 41-50 years(20%). CNS neoplasms least 
commonly occurred in the 70- 80 years age group (2%) in our study. This was 
in accordance to the study of  N.B.Andrew et al74 where the mean age of 
occurrence was 39 years. Studies conducted by A.Das et al1, and Aryal G37 and 
Manoharan et al75 showed an increase in the incidence of CNS tumors as the 
age increases. 
 N.Manoharan et al75 showed that the CNS tumors were more common in 
the male population (65%) than in the females in Delhi . Similarly there was a 
male predominance (54%) in our study. This was against the CBTRUS14 data 
(female 57%) and the study of Chang Hyun16 (58 % in females). This 
discrepancy could have been because of more number of meningiomas that 
predominated in the females in these studies. 
  Sites of CNS tumors are significant in many aspects. Arrie Perry85  states 
that because the central nervous system is a complex structure with  various 
subdivisions that have differing functions and different susceptibility to 
particular neoplasms, it is not only important to designate the overall site of the 
tumor like brain, spinal cord, nerves but also to specify the region of the brain 
and meninges like frontal, temporal, parietal. Such designations are of great 
value for future studies as the behaviour of the CNS tumors varies by site. Eg 
there is different prognosis of a frontal convexity meningioma in comparison to 
one growing along the sphenoid wing. Moreover according to Jill et al104 
relative survival rates (%) did differ by primary site, with tumors in the 
cerebrum, parietal lobe, occipital lobe and overlapping lesions of the brain 
having the poorest survival, less than 20 %  at 5 years. The commonest site 
of CNS neoplasm in our study was in the frontal lobe (25%) followed by the 
parietal lobe (23%).  This was in accordance with the studies of N.BAndrew et 
al74 and Chang et al16. Whereas Intisar et al44 showed a predominance in the 
parietal lobe. 
  According to Douglas Miller24, Pathologist could likely construct 
elaborate grading schemes for tumors in general and astrocytomas in particular, 
with any number of different categories. These might be reproducible, teachable 
to others, and they might be even based on objective observations on which 
multiple observers could reliably agree. The point of tumor grading however is 
to provide a statistical observation derived from populations of tumor patients 
but applied to an individual case presently under observation in order to guide 
therapeutic decisions and give a sense of the survival probability for the patient 
represented by the case. 
Grading of the CNS tumors in this study was done according to the WHO 
2007 criteria51. The grading was based on the cellularity, mitotic count, 
microvascular proliferations, necrosis. In our study it was seen that the grade I 
tumors were more common (42%) with lesser occurrence of grade IV tumors 
(27%) . Also it was noted that grade I and grade II tumors occurred more 
commonly in the third decade in accordance with the study of Peter et al who 
showed a similar occurrence in grade II tumors. Grade IV tumors had bimodal 
peak of occurrence in the second and in the fourth decade. 
Sex wise incidence showed that the females (53%) outnumbered the 
males (33%) in grade I tumors that was because of many cases of meningiomas 
in our study that usually have a predilection for females, whereas males 
predominated in all other grades of CNS neoplasms. 
A comparative analysis of the incidence of various CNS tumors at 
different geographic locations by various studies14,62,37,11 is shown in the 
following table (chart- 14) 
Table – 17 Comparison of incidence of CNS tumors in various studies 
Tumor CBTRUS Ejas et al Aryal.G Bushra Ayaz Our study 
Astrocytoma 23.7 % 41% 38.6% 48% 45% 
Meningioma 31.4 % 23% 14% 18% 23% 
Medulloblastoma 1% 2.4% 3.5% 4% 7% 
Pituitary adenoma 13.1% 2% 5.2% - 4% 
Nerve sheath tumors 8.6% 11% 8.7% 1% 13% 
Ependymoma 1.8% 4.8% 1.8% 6% 2% 
Hemangioblastoma 0.8% - - 4% 2% 
Oligodendroglioma 2% 4.8% - 8% 1% 
Ganglioglioma 0.2% - - - 1% 
Others 19.2% 11% 28.2% 11% 2% 
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The distribution of various CNS tumors in our study showed that 
astrocytomas were the top on the list constituting about 43 % followed by 
meningiomas 23%, which is in accordance with other studies of M. Ejas et al62, 
Aryal G32 and  Bushra et al11. According to CBTRUS14, meningiomas ranks the 
first followed by astrocytomas.  Nerve sheath tumors occupies the third place in 
the studies by M Ejas62 and the present studies.(chart-14) 
Incidence of glial tumors in various institutions in India76 in comparison 
with our study is shown below 
Table – 18 
Incidence of glial tumors in various institutions in India 
Study  Astrocytoma  Glioblastoma Medulloblastoma  Oligodendroglioma  Ependymoma  
Tata 
Memorial 
Hospital, 
Mumbai 
46.3% 21.5% 11.1 6.3% 6.8% 
Kidwai 
Memorial 
Institute of 
oncology 
Bangalore 
41.1% 22.95% 11.2% 9.6% 1.92% 
Cancer 
institute,Ad
yar 
39% 29.05% 5.9% 4.4% 3.4% 
Regional 
cancer 
institute,Tri
vandrum 
41.35% 13.3% 12.7% 3.35% 2.1% 
Assam 
Medical 
college, 
Dissugarh 
46.75% 7.1% 8.1% 9.1% 7.1% 
Present 
study 25% 20% 7% 1% 2% 
The above tables show that astrocytoma is the most common glioma in 
our study consistent with other studies in various institutions. Astrocytomas are 
primary CNS tumors that was previously classified in to three histological 
types: Fibrillary astrocytoma (WHO grade I and II), Anaplastic astrocytoma       
( WHO grade III) and Glioblastoma (WHO grade IV). The reason for 
classification and grading of astrocytomas is to help in chosing the right 
management  protocol. 
 Astrocytomas are further graded by the WHO based on the nuclear 
atypia, mitosis, microvascular proliferations and necrosis ( AMEN criteria)51 
into four grades. The following are the incidence of various grade of 
astrocytomas in different studies 
Table – 19 
Comparison of grades of astrocytomas with other studies 
 
 The above table 19  (chart 15)shows that grade IV astrocytomas is the 
commonest grade and grade I astrocytomas shows the least occurrence in 
majority of the studies ( A.Das et al, Aryal G, A and Intisar et al)1,37,44 and it is 
the same in our study also. According to the studies of P Kleihaus et al53 . Grade  
Studies  Grade I Grade II Grade III Grade IV 
A.Das et al 3.3% 2.4% 3.3% 9.3% 
Aryal 27.3% 27.3% 13.6% 31.8% 
Intisar et al 12.5% 8.9% 19.6% 58.9% 
Busra Ajas et al 4% 11% 10% 23% 
Our study 6.9% 23.25% 27.96% 41.86% 
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I and II are common in the 30-40 yrs age group which is consistent in our study 
also, whereas the grade IV astrocytomas occurred in a much older age group 40- 
50 years which is consistent with the study of Zulch KJ et al who gave a peak 
incidence between 45- 70 years.(chart- 15 
Regarding the sex wise incidence of various grades of  astrocytomas our 
study showed an increase in incidence in males (67%) in all the grades than in 
the females (33%). This is in accordance with the study of A.Das1 and Intisar et 
al 44who also showed an increase in incidence in the males.  
Meningiomas are relatively common intracranial neoplasm in India. The 
majority occur in the elderly age group. Meningiomas are generally benign 
neoplasms and although they exhibit a variety of well described histologic 
patterns, none of these have any bearing on the prognosis. Instead the prognosis 
is influenced by the completeness of excision and aggressive nature with 
increases mitosis, necrosis and prominent cytological atypia.93 
Meningiomas constituted the second largest group of CNS tumors  in our 
study (23%). This was comparable to the study of NB Andrew et al74(19.2%), 
Ejas et al62 (23%). All the cases were graded on the basis of the WHO criteria 
which included cellularity, pattern, mitosis and necrosis. Out of the 23 cases, 
grade I tumors constituted about 19 cases – 82.6%) and this is similar to the data 
of Sameh et al102 (86.5%) and Sasidhar et al103 ( 90%). One case of rhabdoid 
meningioma (grade III) was observed in our study. Only one case of atypical 
meningioma ( grade II) was observed constituting about 4.3%. Jaas kelainen et 
al45 also showed an incidence of 1-2.8 % for grade II meningiomas. 
According to the study of Paul Kliehaus et al52 and Mahmood et al 63 
meningiomas are common in the sixth and the seventh decade. In contrast our 
study showed  an increase in incidence in the third and the fourth decade            
(26.085 and 21.73%). An increased incidence was noted in the females(87%) 
which correlated with majority of studies done worldwide. According to Perry 
A et al85 atypical and anaplastic meningiomas may show a conspicuous male 
predominance, but this fact did not correlate in our study as both the cases of 
grade II and grade III meningiomas occurred in females. Another interesting 
fact regarding the sex incidence is that  according to Sheik et al107, Hope JK et 
al40 and Erdincler  P et al31 childhood meningiomas are more common in males 
and spinal cord meningiomas were more common in females. In our study we 
have no such incidence of meningiomas in the spinal cord. 
The nerve sheath tumor were the next more common tumors in our study. 
Schwannomas constituted about 9 % and neurofibromas about 8 %. One case of 
low grade MPNST was reported from the spinal cord. Intisar et al44 showed an  
incidence of 3.9% for schwannomas and 2.4 % for neurofibromas. The mean 
age of occurrence was about 35 years for all nerve sheath tumors. Also there  
was an overall male predominance with the male female ratio of 1.3:1,which 
correlated with Intisar et al (1.5:1). All the neurofibromas occurred in the spine 
8%) and most of the schwannomas occurred in the CP angle.many vestibular 
schwannomas are predominantly Antoni A tissue and relatively hypercellular 
compared to other locations and lack the nuclear pallisading according to Celli 
et al 13 According to a recent study in a series of 430 spinal tumors, unlike 
schwannomas , neurofibromas are uncommon in the cranial and spinal nerves  
constituting only 6 cases(Engel et al)30. We reported one case of  MPNST  in  a 
35 years old female in the D1-D3 level of the spine. According to Ducatman 
BS26 et al MPNST is a very rare tumor in the spinal cord constituting only about 
0.001 % of the reference population. As in our case this tumor is more common 
in females. Prognosis of MPNST  arising primarily from the spine in not good ( 
Celli et al ).  Seppala MT et al105 in his study has shown that  there is a 71 % 
recurrence rate and metastasis to the lung in 33 % of cases.As per the study of 
N.B Andrew et al74 spinal cord tumors constituted to about 13% of CNS tumors 
and according to Bushra et al11 it constitutes to 15 %. In our study we have 
found an incidence of 9% of spinal tumors out of which 7( 78%) were neural 
tumors and there were one case each of meningioma(11% and myxopapillary 
ependymoma (11%) 
Hemangioblastomas are highly vascular tumors which occupy a special 
niche in the universe of primary CNS neoplasms they are formed of two 
principal components, vascular elements and interstitial or stromal cells. The 
varied ratios of these two elements, the calibre of the vascular channels 
(predominantly capillaries) and the degree of lipidization of stromal cells 
contribute to the histological heterogeneity of hemangioblastomas. Two cases of 
hemangioblastomas were reported in our study constituting 2% of CNS tumors. 
This was in accordance with the  studies of A.Das1(2.2%)and Miyagami et al 72 
(2.1%). Both the cases occurred in males. Hemangioblastomas  are slow 
growing tumors that commonly occur in the cerebellum and occur in association 
with Von Hippel –Lindau  disease. In our study one case occurred in the 
cerebellum but other occurred in the parietal lobe. No syndromic association 
was noted in both cases. Miyagami et al72 have emphasized that sporadic 
hemangioblastomas have a good long term prognosis in contrast to the familial 
VHL disease associated hemangioblastomas. 
Oligodendrogliomas constitute about  3 % of the total CNS neoplasms.  
As per the study by Manoharan et al75 conducted between 2003 and 2007 with a 
total of 1989 patients showed an incidence of 5.2% for oligodendrogliomas. We 
reported one case of oligodendroglioma in a 30 years old male . Most frequent 
age of occurrence is between 40 and 45 years according to Arie Perry et al85. 
The classical fried egg appearance of the neoplastic cell and the rich branching 
chicken wire type of blood vessels were observed in our study. 
Pituitary adenomas represent about 10-20 % of the intracranial 
neoplasms110. According to Richard A Prayson93,the histopathological 
identification of a pituitary adenoma is usually a straightforward even easy 
enterprise. So long as the tissue is submitted as from the pituitary and not 
labelled generically as “brain tumor”. Some adenomas exhibit medium sized 
cells with a round nuclei in the centre of clear cytoplasm, which may be 
mistaken for oligodendroglioma and its mimics. Some adenomas have a 
distinctive perivascular arrangement suggestive of ependymomatous pseudo 
rosettes. Hence without a proper designation as to site might misdiagnosed and 
is essential that the pathologist know the location from which the tissue comes.  
Aryal .G reported that the peak age of occurrence was in 21-40 years age group.  
We reported 4 cases of pituitary adenomas. We have observed  a wide 
variation in the age of occurrence, one in a 10 years old male child and the the 
oldest reported case was in a 70 years old male. The other 2 cases were in 
women in the third decade . Literature shows that pituitary adenomas are more 
common in the female population. In our study we had a equal sex incidence. 
All the cases in our study were macroadenomas > 1 cm diameter.  
Ependymomas are tumors that occur in children and young adults and 
favour the fourth ventricle and spinal cord. In grade II ependymomas there are 
perivascular pseudorosettes, ependymal canals, rare or no mitosis.Grade III 
(anaplastic) ependymomas show increased cellularity, brisk mitotic activity, 
vascular proliferation, endothelial hyperplasia, pseudopallisading necrosis, 
perivascular rosettes and ependymal canals.53 
Two cases of ependymomas was included in the study. We reported a 
case of myxopapillary ependymoma in a 55 years old male. The other case of 
ependymoma was reported in a 32 years old male. The age group did not tally 
with  most of the literature. A study by Suri et al111 showed that the mean age of 
occurrence in his study was 40 years. Arie Perry85 showed an equal male female 
ratio. But in our study both were males. 
  Myxopapillarv ependymomas (grade I) are characterized by cuboidal to 
elongated tumor cells around vascularized stromal cores in a mucoid matrix. 
Myxopapillary ependymoma occurred in the spinal cord at the D12 - L1 level. 
But  the site of occurrence of the grade II ependymoma was unusual to be in the 
frontal lobe. Suri et al111,showed that there was a 2.16% of occurrence of 
ependymomas intracranially. Xuetao et al124 also showed that there can be 2-9 
% occurrence of ependymomas intracranially.  
One case of ganglioglioma was reported in a 42 years old male 
constituting 1% of all CNS neoplasms. Wolf et al in his study showed a similar 
incidence and Arie Perry85 showed an incidence of < 2% in his study. 
According to Lay Ken56  they occur in 2 nd- 5th decade and are associated with 
seizures. They are characterized by the biphasic tumor cell population with 
neuronal and glial elements. Hirose et al stated that the glial population is the 
actively dividing component and  most cases being grade I or II . Dysmorphic 
haphazardly arranged ganglion cells dispersed in a glial background was well 
observed in our study.  
Two cases (2%) of metastatic tumors were reported. The tumors occurred 
secondary to the adenocarcinomas in the colon. Both the cases demonstrated 
mucin secreting well differentiated glands. One case was in the parietal lobe and 
the other was in the occipital lobe. Both cases were in the fourth decade and had 
equal sex incidence. This was in contrast with the study of  Paul Kleihaus et al53 
who showed an incidence of 0.03 to 0.04 % with the rate of metastasis higher in 
the elderly age group. 
                      CHILDHOOD BRAIN TUMORS 
An estimated  2400 children between the ages of  0-19 years are 
diagnosed with invasive primary central nervous system tumors in the United 
100,000 person years  (CBTRUS report 2009)12 . Brain  tumors are second only 
to acute lymbhoblastic leukemia (ALL) in children. The incidence of CNS 
tumors in children as stated by Smith, Freidlin et al was found to have increased 
by 35 % between the years 1975-1984. This increase was attributed to the 
introduction of  magnetic resonance imaging (MRI) brain growth occurs rapidly 
during gestation and peaks around 4 months after birth but continues until 3-4 
years thereafter according to   Baldwin and Preston –Martin85 . Hence it is more 
vulnerable to genotoxic damage and neoplastic transformation than any other 
organ in the body, due to the relatively longer course of development both in 
utero and post natal life during which the rapidly dividing cells become 
susceptible to exposure to potential environment toxins and DNA damage.it 
appears that fetal brain is less able to efficiently repair DNA alkylation induced 
by various mutagenic agents. The blood brain barrier is also not complete in the 
fetal brain and facilititates free transfer of carcinogens into the vulnerable neural 
tissue.          
Only about 5 % of the CNS tumors  are the direct consequence of a 
specific gene defect. Ron, Modan et al 98  has stated that occurrence of  majority 
of  these neoplasms are multifactorial  due to the interplay of  both genes and 
the environment. One known environmental cause of brain tumors is ionising 
radiation and can induce both benign and malignant gliomas or occasionally 
primitive neuro-ectodermal tumors (PNET)  
A total of 13 cases(13%) of pediatric brain tumors occurred in our study. 
A similar incidence was reported in the study of Manoharan et al 75 (9.3%) and 
Ayush et al (14.8%). According to the CBTRUS14 data (2009) about 7 % of the 
reported brain tumors occurred in children. Pakistan armed forces medical 
journal11 reported a 7.4% incidence of childhood brain tumors.  
The following were the distribution of various groups of CNS tumors in 
children in comparison with various studies. 
 
 
 
    Table- 20 
       Comparison of incidence of childhood brain tumors with other studies 
Tumor CBTRUS Chang 
et al 
Mehedi 
et al 
Ayushi 
et al 
Manoharan 
et al 
Our 
study 
Medulloblastoma 13% 13.5% 34.5% 22.4% 26.35 53.8% 
Astrocytoma 29.1% 22% 29% 34.7% 34.6% 23.07% 
meningioma 1.9% 5.3% 2.2% 3.2% - 7.69% 
Nerve sheath tumor 4.7% 6.6% - 3.6% 0% 7.69% 
Pituitary tumor 3% 11.5% - - - 7.69% 
 
The spectrum of childhood brain tumors in the present study (chart 16) 
showed a predominance of medulloblastoma which seem to contrast with all 
theinternational studies ( CBTRUS14, Chang et al16 (korea),Mehidi et al 68 
(Morocco), Ayushi et al4)   including the Indian study of Manoharan et al75 who 
showed a predominance of Astrocytomas. The overall male to female ratio in all 
the studies of Cho KT et al17, Farinotti et al32, Mehrazin et al69, Rickert CH et 
al94, Wong TT et al123 indicated that pediatric brain tumors are more common in 
males than in the females, which is in contrast with our study  where females 
predominated (61.5%). 
Over 90 % of the medulloblastoma typically arise from the superior 
medullary velum, grows and fills the cavity of the fourth ventricle. 
Dissemination to leptomeninges occurs in 10 -30 % and spread to the neuraxis 
occurs in < 10 %. Medulloblastoma is the most common malignant brain tumor 
in children. About 400 children are diagnosed with this tumor each year in the 
United States.The peak age of onset is between 5 -9 years of age. 
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 Most common  malignant childhood tumor according to  the studies of 
Mehdi et al68 and Rosalva et al99  is medulloblastoma (28.9%) with the peak 
incidence in the 5 -9 years age group.  Out of the 13 cases of pediatric brain 
tumors in our study there were 7 cases of meduloblastomas. The mean age of  
occurrence of  the tumor was in the  10 years.  
Pediatric gliomas accounted for 52.6% of all brain tumors in children in 
the studies of Chang et al16. High grade gliomas including  grade III and grade 
IV constitute about 14% in the study  of  Sri Gururangan et al109, whereas GBM 
contributes to only 3% in the study of Chang and CBTRUS. In our study GBM 
accounts for 23.3 % of all childhood brain tumors. We reported 3 cases of high 
grade gliomas in our study out of which 2 cases of gliosarcoma was reported .   
Gliosarcoma is a rare primary malignancy of CNS classified by the WHO 
as a high grade glioma and a variant of GBM with similar clinical presentation.  
According to Gilanis et al34 gliosarcomas constitute to about 2% of 
glioblastomas.  In contrast to other CNS tumors it can metastasise outside the 
neuraxis (Koul et al). Neoplastic cells of a glioblastoma divergently 
differentiate into spindle shaped collagen producing mesenchymal cells that 
form fascicles of sarcoma like tissue interspersed with pockets of more glial 
tumor cells creating a more distinct biphasic appearance.(BIOPSY INT). 
According to REIS et al92 genetically gliosarcomas are similar to primary GBM 
except that they have not been shown to have amplification of EGFR the 
sarcomatous element was originally thought to be a second malignant neoplasm 
arising from the perivascular fibroblasts in proliferating vessels, but it has been 
shown to have the same TP 53 and PTEN point mutation as the glial component 
suggesting a common origin. According to Kleihaues et al53 gliosarcoma can 
occur at any age. It is uncommon in children and it peaks in 50-70 years age 
group.P Koul et al 79also suggests the incidence to be in the same age group. 
Gliosarcoma is a very rare tumor entity in children, but Michael 
Kareman70 has reviewed 23 cases of pediatric gliosarcoma  ( 4 cases from 
German HIT-GBM database and 19 cases from English medical science 
literature) and has concluded that it is more common in infants and in patients 
with history of previous cranial radiotherapy. He also observed that the median 
age of gliosarcoma to be 11 years. Kleihaues53 stated that gliosarcoma occurring 
in the first and second decades show a predilection for males but female 
predominance is noted as age advances. Both cases in our study occurred in 15 
years age group and both the cases were females. 
 Most common age of occurrence is the fourth – sixth decade.Age and sex 
incidence of gliosarcoma  shows a peak in the first and second decade in the 
females following which the males show a predominance  In our study two 
cases(2%) of gliosarcoma were reported which was in accordance with the 
study P.Koul et al79 who showed an incidence of <2% of all gliomas. Both cases 
occurred in 15 years age group and both cases were females. Pediatric 
gliosarcoma has been described with no difference in morphology or clinical 
features. It is more common in infants with previous history of radiotherapy. In 
his study Michael Karreman et al70 showed a median age of occurence of 
gliosarcoma to be 11 years. As per the literature the gliosarcomas showed a 
strong predilection for the cerebral hemispheres in our study also.  
 In gliosarcoma the sarcomatous element resembled fibrosarcoma: the 
tumor cells were elongated and spindly and they organised into fascicles of 
parallel cells. Reticulin stains demonstrated a single cell pattern of reticulin 
positivity, whereas the pure glial areas of the same tumor was reticulin negative 
but stained positively for GFAP.24 (fig 7,8) 
Malignant meningiomas are uncommon comprising between 1 -2.8 % of 
meningiomas ( Mahmood et al63,  Jass et al45). Rhabdoid variant is an apparently 
recent addition to meningioma family. Keppes et al125 in their studies have 
quoted that Rhabdoid meningioma was first described in 1998 as an unusual 
variant of meningioma and it is an histological indication of increased 
proliferation activity. 
Histologically the descriptor rhabdoid refers to both the cytoplasm and 
nuclear configuration wherein gemistocyte appearing eosinophilic cytoplasm 
often shows displacement of nucleaus by spherical mass of intermediate 
filaments. This change may be present diffusely throughout the lesion or focal 
int he background of a more classical meningioma pattern. The pattern often 
emerges during tumor progression and is therefore more obvious in recurrences 
than in the initial specimen.( Keppes et al)125. However Maier et al64 have 
stressed that unless the rhabdoid cells constitute half or more of the lesion it 
does not meet he WHO 2007 criteria for the diagnosis of rhabdoid meningioma. 
As per Douglas C Muller24 and Perry et al81, pediatric meningiomas are 
distinctly rare but are more likely than adult counterpart to manifest aggressive 
behaviour or aggressive variant histologically and they lack any female 
predominance. Predisposing factors often include NF-2 or history of prior 
radiation, although half are still sporadic. In comparison with adult cases, 
clinical behaviour is more difficult to predict. 
There were conflicting reports about the influence of age and gender on 
the proliferative potential and recurrences of meningiomas. Illiden et al43 
reported that age and gender has no influence on proliferative activity. Kosuya 
et al50 reported that male gender was an important risk factor for high 
proliferative potential. As per Sasidhar et al103 proliferative potential age and 
gender is not statistically significant. In the studies of  E.Y.Kim et al28 rhabdoid 
meningiomas occur mainly between 40-60 years with female predominance 
(75%). In contrast Mahmood et al63 have stated that atypical and malignant 
meningiomas usually present earlier than benign meningiomas. Buccoleira et al9 
have one case of rhabdoid meningioma in a three years old child. In correlation 
with the above study we have encountered a case of pediatric rhabdoid 
meningioma in a 10 years old child. But one special feature regarding the sex 
incidence is that in contrast to the lack of female predominance in aggressive 
pediatric meningiomas this case occurred in  a female child.  
There are some reports about the relationship of malignant meningiomas 
and higher incidence of cyst formation as per Guthrie BL38. Vassilouthis et al118 
have included cystic component as one of the CT criteria to evaluate histologic 
aggressiveness of meningiomas. But no such cystic component has been 
identified in our study.E.Y Kim et al28 have commented the improved prognosis 
of rhabdoid meningiomas attributing to the added effect of adjuvant radiation 
therapy in their follow up period. Hence owing to its rarity each new case 
should be recorded to produce better clinical and pathological prognostic and 
therapeutic characterisation of these lesions. 
Pituitary adenomas in children are relatively infrequent occurrences . 
most studies report the incidence of these tumors to be between 1 % and 10 % 
of all surgically treated adenomas. Despite the rarity of these tumors they can 
have a significant effect on the quality of life of the patient, especially during 
childhood, when the growth rates and development are at a peak. Christopher 
web et al18 suggested the fact that most of the pituitary adenomas are secretory 
with prolactinomas being the most common type. They also reported that in 
there study 60 % were macroadenomas. 
 The clinical  presentation of prolactinomas is sexually dimorphic with 
females presenting at  a younger age with microadenomas, because they have a 
prolactin responsive breast and endometrial tissue, whereas the males present at 
a much older age group  with macroadenomas  with compressive symptoms like 
headache or visual problems . Kane LA  et al49 and Minderman Twilson et al71 
in their studies have evaluated that adenomas occurring in children are usually 
PRL or ACTH producing. In accordance , in our study we have reported one 
case of pituitary adenoma in a 10 years old child that presented as a 
macroadenoma (> 1cm) and was already evaluated outside as prolactinoma. 
Pediatric pituitary adenomas are quiet variable in their presentation. 
 Regarding the sex incidence as per Randall RV et al89 and Christopher 
Web et al18, most prolactinomas arise in women of reproductive age group. 
Reidl M  et al91 have stated that prolactinomas present at a older age in males. In 
contrast in our study we have encountered the incidence of prolactinoma in a 
pediatric male patient which goes along with the studies of Comb MC et al67 
who suggest that interestingly prolactinomas show no sex predilection. Lipper 
et al57 has inferred that approximately in 10 % of cases presence of 
psammomatous calcification in hematoxylin and eosin stained section is a 
diagnostic clue and Webster et al has added that calcification in rare in other 
forms of adenoma. In our case of prolactinoma we did not observe this feature 
of calcification 
IMMUNOHISTOCHEMISTRY 
Ki-67 is an intranuclear protein, which is present in the proliferating cells. 
It is present in the cells of all phases of cell cycle namely G1, S, G2 and M 
phase except G0 phase where the cells are in quiescent or resting stage. Thus, 
determination of Ki-67 is an excellent factor correlating cellular growth. MIB-1 
labelling index is the number of  Ki -67 labelled tumor nuclei expressed as a 
percentage of the total number of tumor nuclei counted. A total of atleast 1000 
tumor nuclei were counted in in several areas where the positively stained 
nuclei were  evenly distributed according to Torp SH et al115 . 
All Pathologist will quickly concede , counting mitotic figures in 
haematoxylin and eosin sections can be extremely cumbersome and time 
consuming, particularly if the specimen is large or tissue preservation is poor 
such that it is difficult to distinguish degenerating cells from mitosis Arrie 
Perry85 
The WHO has resisted assigning any specific labelling index cutoffs in 
grading of individual tumor types because there is too much of interlaboratory 
variability . Wide ranging differences in staining results and counting methods 
making it difficult to extrapolate the results from one medical centre to another 
as per Johannesen et al47, Prayson RA86. Arrie Perry and Danial Brat85 in their 
text has stated that keeping in mind that each tumor type is different , a useful 
though grossly oversimplified approach is to consider low, moderate and high 
proliferative indices as less than 5%, 5-10%  and > 10% respectively  
 We evaluated  the Ki 67 expression in various CNS tumors in our study. 
The expression of  Ki-67 varied widely in each study and there is no specific 
cutoff levels to grade  any CNS tumor. The variation in immunoreactivity may 
be due to different expression during the cell cycle. In our study the expression 
of  Ki- 67 correlated well with the histological grade of  all CNS tumors. The 
following table shows the labelling index in astrocytomas in our study in 
comparison to other studies. 
Table – 21 
Comparison of Ki-67 expression in various grades of of astrocytomas 
with other studies 
STUDY Grade I Grade II Grade III Grade IV 
Moses 
Ambroise et al61 3.78 % 2.76% 7.45% 13.85% 
Wakimoto et 
al119 - 3.8% 18.4% 31.6% 
Rahti et al90 - 1.75% 8.74% 20.54% 
Ralte et al88 0.44% 3.73% 9.65% 10.33% 
Tihan et al114 1.83% 3.7% 11.4% 20.2% 
Rodriguez et al97 - 10% 34% 46% 
Giannini et al36 4.8% 5.2% 32% 40% 
E Jaros et al27 1 3 12 20 
Our study <1% 2% 20% 50% 
 
 
In our study  Ki- 67 expression did not exactly correlate with any of the 
other studies but It should be noted that the MIB -1 labelling index did correlate 
with the increasing tumor grade. All other studies22, 41, 66 also showed a marked 
variation in there values. Ki-67 labelling index in  our study can also be added  
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as a reference for future studies. Gliosarcoma ( grade IV astrocytoma) 
showed a maximum expression of Ki-67 (60 %) in our study indicating the high 
grade nature of the tumor with high proliferative activity.(chart -17) 
 Ki 67 expression in meningiomas also correlated well with their 
corresponding   histological grades. The following  table shows  a comparison  
of  Ki 67 labelling in meinigiomas with other studies. 
Table – 22 
Comparison of Ki-67 expression in different grades of meningiomas 
Study Grade I Grade II Grade III 
Meram et al 2.2% 6.5% 11.1% 
Nakasu et al 1% 2.75% 9% 
Karamito poulou 1.3% 9.3% 25% 
Sashidhar babu et 
al103 
4% 11.2% 18.22% 
Our study 1% 10% 20% 
   
According to the above table 22  and chart -18  it is seen that our study showed 
almost similar labelling index as in the studies of   Sashidhar babu et al103. The 
labelling index correlated well with increasing grades of meningiomas as in the 
other stuies of Ohta M et al78 and Pinnar Karbagli et al83 87. Kesavan et al79 
reported an expression of 20 % in a case of Rhabdoid meningioma  ( Grade III) 
which was the same with or study too ( 20%)100,106   
 Oligodendroglioma  being a grade II  tumor showed a 0. 5 % expression 
of  Ki 67 which correlated with the study of Jaros et al27  who showed an  
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expression of 0.6 % in oligodendrogliomas. This was also in accordance with 
the study of Coons SW et al20,21 and the study of  Kros JM et al 54 
In case of medulloblastoma the expression of  Ki 67 was 5 % in our 
study. This percentage of expression of Ki 67 was  less when compared with the 
study of Rosalva et al99 who showed an average expression of  27.5%. 
  Ki 67 labelling was  negative in case of ganglioglioma in our study. 
Wolf et al122  in his study of 61 cases of gangliogliomas showed that  in 74 % of 
cases the  Ki 67 labelling index was < 1 %. He also showed that the labelling 
happened only in the astrocytic component of the tumor. 
  In case of  pituitary adenoma the labelling was negative. According to 
Shrestha et al80 and  Prabin et al84  Ki 67 expression in pituitary adenomas is 
often <1 %. But Luciano et al60 in his study showed a slightly higher expression 
of  Ki 67 in the range of  2.72 ± 2.49 %.  
 Ki 67 expression was less than 1 % in case of hemangioblastoma. This 
value correlated with the study of Miyagami M et al72 who showed a mean 
expression of 0.8 % in hemangioblastomas. 
 According to the study of Huma Arshad42 and Suri S Vaishali et al111 the 
labelling index in case of ependymomas was 0.5 %. In our study the value was 
1 %. Nerve sheath tumor usually showed a very low expression of Ki -67 and it 
was about 2% in the study of Saito et al101. In our study Ki 67 expression was        
< 0.1 %. Jaros et al27 also showed a similar expression of 0.2 %.  
The caveats of immunohistochemical analysis using Ki-67 include 
different antigens, background staining and inhomogeneous staining that can 
contribute to interlaboratory and interobservwer variations3. The archieved 
specimens may lose its antigenicity over time and cannot be retrieved 
adequately and thus giving a false low labelling index. 
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CONCLUSION 
 
In  this retrospective study of 100 Central Nervous system tumors that were 
evaluated with histochemical, histopathological and immunohistochemistry, the 
following were the conclusions made and presented. 
1. The incidence of central nervous system tumors  is  
2. High incidence of CNS neoplasms is seen in the 3rd and 4th decade with 
slight male predominance. 
3. Primary CNS tumors commonly occurs supratentorially in adults and 
infratentorially in children. 
4. Astrocytomas constitute the most common CNS tumor, followed by 
meningiomas. 
5. Grading of astrocytomas showed that grade IV  tumors are more 
common. 
6. In children Medulloblastomas are the commonest neoplasm. 
7. Special stains help in the confirmation of certain neoplasms. 
8. Ki-67 has a great value in the histological assessment of neoplastic 
lesions of the CNS. It has to be used prudently in combination with 
histopathological features for designating the exact grade of the tumor 
In developing countries like India due to lack of complete registration of 
newly diagnosed cases of CNS tumors with local cancer registries the exact 
tumor burden goes unnoticed and is underestimated. Hospital based 
prevalence data therefore forms the basis for estimating the tumor burden 
and is essential for ascertaining the required health care infrastructure in the 
management of these cancers.  This can have important connotations in the 
field of brain tumor research particularly  when analysing the geographical 
differences in their molecular and genetic profiles which could aid in the 
development of targeted individualised therapies and planning treatment 
protocols and strategies.  
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ANNEXURE-I 
WHO CLASSIFICATION OF CENTRAL NERVOUS SYSTEM                  
TUMORS 
TUMORS OF THE NEUROEPITHELIAL TISSUE    
  
                ASTROCYTIC TUMORS                                  
1. 9421/1    Pilocytic astrocytoma                                WHO grade I 
9425/3    Pilomyxoid astrocytoma              WHO grade II 
2. 9384/1    Subependymal Giant Cell Astrocytoma     WHO grade I 
3. 9424/3    Pleomorphic Xanthoastrocytoma              WHO grade II 
4. 9400/3    Diffuse Astrocytoma                WHO grade II 
9420/3    Fibrillary Astrocytoma 
9411/3    Gemistocytic Astrocytoma 
9410/3    Protoplasmic Astrocytoma 
5. 9401/3    Anaplastic Astrocytoma                         WHO grade III 
6. 9440/3    Glioblastoma               WHO grade IV 
9441/3    Giant cell Glioblastoma             WHO grade IV 
9442/3    Gliosarcoma       WHO grade IV 
7. 9381/3    Gliomatosis Cerebri  
 
OLIGODENDROGLIAL TUMORS 
8. 9450/3    Oligodenroglioma       WHO grade II 
9. 9451/3    Anaplastic Oligodenroglioma     WHO grade III 
 
OLIGOASTROCYTIC TUMORS 
10. 9382/3    Oligoastrocytoma       WHO grade II 
11. 9382/3    Anaplastic Oligoastrocytoma     WHO grade III 
 
EPENDYMAL TUMORS 
12. 9383/1    Subependymoma      WHO grade I 
13. 9394/1    Myxopapillary Ependymoma     WHO grade I 
14. 9391/3    Ependymoma        WHO grade II 
9391/3    Cellular 
9393/3    Papillary 
9391/3    Clear cell 
9391/3    Tanycytic  
15. 9392/3    Anaplastic Ependymoma     WHO grade III 
 
CHOROID PLEXUS TUMORS 
16. 9390/0    Choroid plexus papilloma      WHO grade I 
17. 9390/1    Atypical choroid plexus papilloma     WHO grade II 
18. 9390/3    Choroid plexus carcinoma      WHO grade III 
 
OTHER NEUROEPITHELIAL TUMORS 
19. 9430/3    Astroblastoma        WHO grade I 
20. 9444/1    Chordoid glioma of the third ventricle    WHO grade II 
21. 9431/1    Angiocentric glioma                 WHO grade I 
 
NEURONAL AND MIXED NEURONAL- GLIAL TUMORS 
22. 9493/0    Dysplastic Gangliocytoma of cerebellum (Lhermitte- Duclos) 
23. 9412/1    Desmoplastic infantile astrocytoma/Ganglioglioma WHO gr I 
24. 9413/0    Dysembryoplastic neuroepithelial tumor   WHO grade I 
25. 9492/0    Gangliocytoma                 WHO grade I 
26. 9505/1    Ganglioglioma                 WHO grade I 
27. 9505/3    Anaplastic Ganglioglioma               WHO grade III 
28. 9506/1    Central neurocytoma       WHO grade II 
29. 9506/1    Extraventricular neurocytoma      WHO grade II 
30. 9506/1    Cerebellar liponeurocytoma      WHO grade II 
31. 9509/1     Papillary Glioneuronal tumor            WHO grade I 
32. 9509/1    Rosette forming Glioneuronal tumor of the fourth ventricle  gr  I 
33. 8680/1    Paraganglioma        WHO grade I 
 
TUMORS OF THE PINEAL REGION 
34. 9361/1    Pineocytoma        WHO grade I 
35. 9362/3    Pineal parenchymal T of the intermediate differentiation             
WHO grade II,III 
36. 9362/3    Pineoblastoma       WHO grade IV 
37. 9395/3    Papillary tumor of the pineal region           WHO grade II,III 
 
EMBRYONAL TUMORS 
38. 9470/3    Medulloblastoma              WHO grade IV 
9471/3    Desmoplastic/Nodular medulloblastoma 
9471/3    Medulloblastoma with extensive nodularity 
9474/3    Anaplastic Medulloblastoma 
9474/3    Large cell Medulloblastoma 
39. 9473/3    CNS Primitive neuroectodermal tumor   WHO grade IV  
9500/3    CNS Neuroblastoma 
9490/3    CNS Ganglioneuroblastoma 
9501/3    Medulloepithelioma 
9392/3    Ependymoblastoma 
40. 9508/3    Atypical teratoid /Rhabdoid tumor    WHO grade IV 
 
TUMORS OF THE CRANIAL AND SPINAL NERVES 
41. 9560/0    Schwannoma           WHO grade I 
9560/0    Cellular 
9560/0    Plexiform 
9560/0    Melanotic  
42. 9540/0    Neurofibroma          WHO grade I 
9550/0    Plexiform 
43. 9571/0    Perineurioma NOS                   WHO grade I,II,III 
9571/3    Malignant Perineurioma 
44. Malignant peripheral nerve sheath tumor (MPNST) WHO grade II, III, IV 
9540/3    Epithelioid MPNST  
9540/3    MPNST with mesenchymal differentiation 
9540/3    Melanotic MPNST 
9540/3    MPNST with glandular differentiation 
 
TUMORS OF THE MENINGES 
Tumors of the meningothelial cells  
45. 9530/0    Meningioma      WHO grade I 
9531/0    Meningothelial  
9532/0    Fibrous  (fibroblastic ) 
9537/0    Transitional (mixed) 
9533/0    Psammomatous  
9534/0    Angiomatous 
9530/0    Microcystic  
9530/0    Secretory 
9530/0    Lymphoplasmacyte – rich 
9530/0    Metaplastic  
9538/1    Chordoid      WHO grade II 
9538/1    Clear cell                WHO grade II 
9539/1    Atypical      WHO grade II 
9538/3    Papillary      WHO grade III 
9538/3    Rhabdoid       WHO grade III 
9530/3    Anaplastic ( malignant)   WHO grade III 
Mesenchymal tumors 
46. 8850/0    Lipoma 
47. 8861/0    Angiolipoma 
48. 8880/0    Hibernoma 
49. 8850/3    Liposarcoma  
50. 8815/0   Solitary fibrous tumor 
51. 8810/3    Fibrosarcoma 
52. 8890/0    Malignant fibrous histiocytoma 
53. 8890/0    Leiomyoma 
54. 8890/3    Leiomyosarcoma 
55. 8900/0    Rhabdomyoma 
56. 8900/3    Rhabdomyosarcoma 
57. 9220/0    Chondroma 
58. 9220/3    Chondrosarcoma 
59. 9180/0    Osteoma 
60. 9180/3    Osteosarcoma 
61. 9210/0    Osteochondroma 
62. 9120/0    Hemangioma 
63. 9133/1    Epithelioid Hemangioendothelioma 
64. 9150/1    Hemangiopericytoma                  WHO grade II 
65. 9150/1    Anaplastic hemangiopericytoma               WHO grade III 
66. 9120/3    Angiosarcoma 
67. 9364/3    Kaposi Sarcoma  
68. 9364/3    Ewing Sarcoma – PNET 
 
PRIMARY MELANOCYTIC LESIONS 
69. 8728/0    Diffuse melanocytosis 
70. 8728/1    Melanocytoma 
71. 8720/3    Malignant melanoma 
72. 8728/3    Meningeal melanomatosis 
 
OTHER NEOPLASMS RELATED TO THE MENINGES 
73. 9161/1    Hemangioblastoma            WHO grade I 
 
TUMORS OF THE HEMATOPOETIC SYSTEM 
74. 9590/3    Malignant Lymphoma 
75. 9731/3    Plasmacytoma 
76. 9930/3    Granulocytic Sarcoma 
 
GERM CELL TUMORS 
77. 9064/3    Germinoma 
78. 9070/3    Embryonal Carcinoma 
79. 9071/3    Yolk sac tumor 
80. 9100/3    Choriocarcinoma 
81. 9080/1    Teratoma 
9080/0    mature 
9080/3    immature 
9084/3    Teratoma with malignant transformation 
82. 9085/3    mixed germ cell tumors 
 
TUMORS OF THE SELLAR REGION 
83. 9350/1    Craniopharyngioma          WHO grade I 
9351/1    Adamantinomatous  
9352/1    Papillary 
84. 9582/0    Granular cell tumor          WHO grade I 
85. 9432/1    Pituicytoma           WHO grade I 
86. 8991/0    Spindle cell oncocytoma of the adenohypophysis  WHO grade I 
                   
ANNEXURE-II 
MASTER CHART 
S.no Patho no Age/sex Site  Clinical diagnosis HPE diagnosis WHO 
grade 
1 261/10 48/M parietal ? tuberculoma GBM IV 
2 263/10 35/F Tentorium meningioma Meningothelial 
meningioma 
I 
3 265/10 45/F Parietal meningioma Transitional meningioma II 
4 326/10 55/F Temporal SOL Astrocytoma II 
5 393/10 45/F Parietal meningioma Transitional meningioma I 
6 433/10 19/M Occipital SOL Astrocytoma III 
7 478/10 16/M Posterior fossa SOL medulloblastoma IV 
8 479/10 19/M D9-D10 SOL Schwannoma I 
9 555/10 52/M Frontal glioma Astrocytoma III 
10 577/10 30/F Frontal SOL Anaplastic meningioma III 
11 668/10 54/F Frontal meningioma Meningothelial 
meningioma 
I 
12 881/10 52/M Frontal Glioma Astrocytoma IV 
13 882/10 40/F Parietal SOL Adenocarcinoma deposit - 
14 915/10 45/M Thalamus glioma Astrocytoma  IV 
15 1149/10 45/M Frontal ? GBM GBM IV 
16 1374/10 48/F CP Angle ? Schwannoma Schwannoma I 
17 1399/10 40/F Parietal SOL Astrocytoma  III 
18 1437/10 35/F Temporal SOL Astrocytoma  I 
19 1439/10 55/F sphenoid meningioma Meningothelial 
meningioma 
I 
20 1621/10 50/M Skull base 
tumor 
SOL Astrocytoma  II 
21 1660/10 40/F Frontal ? GBM Astrocytoma II 
22 1831/10 58/M Parietal Astrocytoma Astrocytoma III 
23 1952/10 32/M Frontal SOL Ependymoma II 
24 1967/10 35/F Tentorial meningioma Anaplastic meningioma III 
25 2141/10 45/F Frontal GBM Astrocytoma IV 
26 2236/10 72/M Temporal SOL Astrocytoma IV 
27 2307/10 33/M Parietal SOL Astrocytoma IV 
28 2401/10 51/M Frontal SOL Astrocytoma II 
29 2452/10 32/F Sellar fossa SOL Pituitary adenoma I 
30 2487/10 7/M Posterior fossa medulloblastoma Medulloblastoma  IV 
31 2526/10 14/M Posterior fossa SOL Medulloblastoma  IV 
32 2636/10 70/M Suprasellar SOL Pituitary adenoma I 
33 2738/10 11/M Posterior fossa SOL Medulloblastoma  IV 
34 2814/10 45/M Temporal SOL Astrocytoma I 
35 3353/10 29/F Parietal meningioma Meningothelial 
meningioma 
I 
36 3482/10 10/F Posterior fossa medulloblastoma Meduloblastoma  IV 
37 3683/10 50/F Parietal SOL Astrocytoma IV 
38 3686/10 53/M Frontal ?GBM Astrocytoma IV 
39 3739/10 6/F Posterior fossa medulloblastoma Medulloblastoma IV 
40 3741/10 68/F D8-D9 ? meningioma Psammomatous 
meningioma 
I 
41 3816/10 45/M Occipital ? secondaries Adenocarcinomatous 
deposit 
- 
42 3822/10 40/F Sphenoid wing ? meningioma Transitional meningioma I 
43 3859/10 38/F CP angle ? schwannoma Schwannoma I 
44 3990/10 40/M Parietal ? astrocytoma GBM IV 
45 4128/10 62/M Temporal SOL Astrocytoma III 
46 4211/10 42/M CP angle Schwannoma Schwannoma I 
47 4258/10 37/F Suprasellar Meningioma Meningothelial 
meningioma 
I 
48 7/11 55/M D12-L1 Ependymoma Myxopapillary 
ependymoma 
I 
49 100/11 65/M L2-L3 ? neurofibroma Schwannoma I 
50 233/11 38/M Parietal SOL Astrocytoma II 
51 272/11 33/M Parietal glioma Astrocytoma II 
52 504/11 56/F Temporal Astrocytoma Astrocytoma III 
53 723/11 9/F D1-D3 SOL Neurofibroma I 
54 734/11 40/F Occipital GBM Astrocytoma IV 
55 830/11 10/M Supra sellar SOL Pituitary adenoma I 
56 834/11 65/M Sphenoid wing Meningioma Transitional meningioma I 
57 1110/11 12/M Posterior fossa medulloblastoma  Medulloblastoma  IV 
58 1167/11 35/F Sellar SOL Pituitary adenoma I 
59 1383/11 13/F Frontal SOL GBM IV 
60 1416/11 65/M Parietal SOL Hemangioblastoma I 
61 1561/11 33/M Frontal SOL Atypical meningioma III 
62 1839/11 45/F Parietal SOL Psammomatous 
meningioma 
I 
63 1951/11 26/M Parietal SOL Astrocytoma III 
64 2030/11 30/M Temporal Glioma Astrocytoma III 
65 2031/11 23/M Posterior fossa Recurrent SOL Hemangioblastoma I 
66 2032/11 26/M C5-C6 Neurofibroma Neurofibroma I 
67 2484/11 40/M Parietal Glioma Astrocytoma I 
68 2630/11 26/M Frontal Glioma Astrocytoma III 
69 2771/11 55/F Parietal ? meningioma Transitional meningioma I 
70 2890/11 55/F L1-L2 neurofibroma neurofibroma I 
71 2936/11 53/F Frontal meningioma Meningothelial 
meningioma 
I 
72 3055/11 35/F D1-D3 SOL MPNST- low grade II 
73 3303/11 30/M CP angle SOL Schwannoma I 
74 3380/11 45/M Frontal SOL Meningothelial 
meningioma 
I 
75 3401/11 35/F Parietal SOL Meningothelial 
meningioma 
I 
76 3523/11 26/F Parietal Glioma Astrocytoma III 
77 3730/11 43/M Frontal GBM Astrocytoma IV 
78 3841/11 28/F Frontal Glioma Astrocytoma IV 
79 3929/11 42/M Frontal Glioma Ganglioglioma I 
80 4113/11 48/F Frontal ? meningioma Meningioma I 
81 4327/22 29/M Parietal Gliotic cyst Astrocytoma IV 
82 4535/11 15/F Frontal ? meningioma Gliosarcoma IV 
83 4670/11 55/F Frontal ? meningioma Transitional meningioma I 
84 215/12 25/F Frontal Glioma Astrocytoma IV 
85 217/12 30/M Parietal Glioma Oligodendroglioma I 
86 295/12 30/M Parietal Glioma Astrocytoma II 
87 299/12 80/F Parietal Meningioma Transitional meningioma I 
88 338/12 15/F Frontal GBM Gliosarcoma IV 
89 390/12 20/M D7-D8 SOL Schwannoma I 
90 500/12 49/M CP angle SOL Schwannoma I 
91 539/12 35/M Temporal SOL Astrocytoma II 
92 628/12 23/F temporal SOL Astrocytoma II 
93 819/12 55/F Temporal ? meningioma Astrocytoma IV 
94 909/12 65/F Parietal Meningioma Meningothelial 
meningioma 
I 
95 934/12 47/M Frontal SOL Astrocytoma III 
96 1261/12 10/F Temporal SOL Rhabdoid meningioma III 
97 1380/12 40/M Frontal SOL Astrocytoma III 
98 1475/12 27/F Frontal ? glioma Astrocytoma III 
99 1537/12 40/M CP Angle SOL schwannoma I 
100 1827/12 47/M Parietal SOL Astrocytoma IV 
 
 
 
 
ANNEXURE-III 
HAEMATOXYLIN AND EOSIN 
Preparation of the solution – HARRIS HEMATOXYLIN 
• Distilled water  - 1000 ml 
• Ammonium  alum -  100 g 
• Haematoxylin - 5 g 
• Absolute ethyl alcohol – 50 ml 
• Mercuric oxide – 2.5 g 
100 g of ammonium alum dissolved in 1000 ml of distilled water by heating and 
shaking at 60 0C. Add solution of 50 g of haematoxylin in 50 ml of ethyl alcohol 
and bring rapidly to boil. When it begins to boil, remove from flame and add 2.5 
g of mercuric oxide. Mix by swirling gently. 
EOSIN STAIN: 
• Eosin Y – 1 g 
• Distilled water – 20 ml 
• 95% ethanol -80 ml 
• Glacial acetic acid -0.2 ml 
Dissolve 1 g eosin Yin 20 ml of water and add 95% ethanol and glacial acetic 
acid 
PROCEDURE: 
1. Bring sections to water  
2. Stain with  Harris  hematoxylin for 15 minutes. 
3. Rinse in tap water 
4. Differentiate with 1% acid alcohol – 3 to 10 quick dips 
5. Rinse in tap water briefly 
6. Allow for blueing in tap water. 
7. Stain with 1% aqueous eosin Y for 15 seconds 
8. Wash in tap water  
9. Dehydrate in ascending grades of alcohol 
10. Clear with xylene  
11. Mount with DPX 
 
ANNEXURE- IV 
RETICULIN STAINING 
Preparation of solution: 
• 1% potassium permanganate 
• 2%  Potassium metabisulphite 
• 2% Ferric Ammonium Sulphate 
• 10% Formalin neutral  
• 0.2% Gold chloride 
• 2.55 sodium thiosulphate 
• 10% KOH 
• Ammoniacal silver solution. 
Preparation of ammoniacal silver solution: 
• 10%  AgNO3 - 40 ml 
• 10%  KOH   - 10 ml 
• Add 40 ml of 10 % Ag NO3 to 10 ml of 10 % KOH in a flask, allow 
silver to deposit 
• Remove the supernatant fluid 
• Wash the deposit with distilled water several times 
• Add strong ammonia drop by drop until the solution takes a faint sheen 
• Make the solution to twice its volume by the distilled water 
Procedure:  
• Section to water 
• Oxidize in potassium permanganate – 2 minutes 
• Rinse in water 
• Decolourize in potassium meta bisulphate – 1 minute 
• Prolonged wash in water – 5 minutes. 
• Sensitise in ferric ammonium sulphate – 1 minute. 
• Prolonged wash in tap water followed by 2 changes of distilled water. 
• Impregate in ammoniiacal silver solution – 1 minute. 
 
 
 
ANNEXURE- V 
IMMUNOHISTOCHEMISTRY 
 
Preparation of Tris Buffered Saline ( TBS): 0.005 M TBS 
Distilled water – 10 litres 
Sodium chloride -80 g 
TRIS (H ydroxymethylamine) – 6.05 g 
1 M Hcl – 44 ml 
Final pH is adjusted to 7.6 with either 1 M Hcl or 0.2 M tris solution 
Preparation of CITRATE buffer solution ( Antigen retrieval solution): 
Trisosium citrate – 2.94 g 
1 N Hcl – 5 ml 
Distilled water- 1000 ml 
Final pH is adjusted to 6.0 with 1N Hcl 
Antigen retrieval: 
The slides are placed in citrate buffer in the coplin jar and capped. The 
jar is then heated in a 750 W domestic microwave oven for 15 
minutes.  5 minutes in low power(40), 5 minutes in medium power 
(60) and 5 minutes in full power (80) pausing only to top up the fluid 
 
Procedure: 
1. Dewax the section in xylene( ½ hr ,  two changes) and bring 
sections to distilled water. 
2. Antigen retrieval using TBS by microwave oven heating 
3. Cool to room temperature in running tap water for 20 minutes 
4. Bring sections to TBS for 5 minutes 
5. Drain and wipe off excess TBS around sections 
6. Incubate in endogenous peroxidise blocking reagents for 15-20 
minutes 
7. Gently wash the slides in TBS  for 5 minutes 
8. Wipe off the excess fluid and incubate with power block for 15 -20 
minutes. 
9. Wipe off the excess fluid and incubate with primary antibody for 
60 minutes. 
10. Repeat steps 4 and 5. 
11. Incubate with super enhancer for 30 minutes 
12. Repeat steps 4 and 5. 
13. Incubate with secondary antibody 
14. Repeat steps 4 and 5. 
15. Incubate in DAB ( Diaminobenzidine) substrate solution for 2-10 
minutes. ( To prepare DAB add 1 ml of substrate buffer, 1 drop of 
liquid DAB) 
16. Wash in distilled water, counterstain with Haematoxylin, clear in 
xylene and mount with  DPX. 
 
RESULTS:  
Tumor marker- Brown 
Nucleus - blue 
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